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ABSTRACT OF DISSERTATION 
 
ON THE ROLE OF CIRCULATING ATP IN VASCULAR CONTROL AT REST AND 
DURING EXERCISE OF AGING HUMANS  
 
The following investigation composes a series of experiments with the overall aim 
of determining the role for the circulating nucleotide adenosine triphosphate (ATP) in 
vascular control at rest and during exercise in humans of advanced age.  We tested the 
general hypothesis that ATP has definite vasodilator and sympatholytic vasomotor 
properties in young adults during exercise, but that these actions are impaired in older 
adults; and that endogenously circulating levels of ATP are diminished during exercise in 
the aged population.  Specifically, the experiments are outlined as such: 1) to determine 
whether exogenous ATP can modulate α-adrenergic vasoconstriction in the human 
forearm of young adults, 2) to determine whether vasodilator responsivene s to 
exogenous ATP is impaired in aging humans, and the contribution of adenosine t  ATP-
mediated vasodilation in aging humans, 3) to determine whether the ability of exogenous 
ATP to modulate α-adrenergic vasoconstriction in the human forearm of older adults is 
impaired similar to the typical response observed during exercise in aged humans, 4) to 
determine whether endogenous venous plasma [ATP] and ATP release is diminished 
during mild-to-moderate exercise in aging humans.  Our collective findings indicate that 
alterations in the contribution of ATP to vascular tone in aging humans exist and may in 
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part be a potential mechanism by which aged adults have reductions in xygen delivery 
to active skeletal muscle.  In particular, circulating exogenous ATP has the ability to 
significantly blunt α-adrenergic vasoconstriction in young adults similar to that observed 
during exercise.  In contrast to our hypothesis, the vasodilatory responsiveness and 
sympatholytic properties of exogenous ATP remain intact in aging humans.  However, 
older adults demonstrate reduced venous plasma [ATP] and impaired ATP release during 
graded mild-to-moderate handgrip exercise which is associated with attenuations in 
skeletal muscle vasodilation and blood flow.  Taken together, it is our belief that the 
typically observed impairments in skeletal muscle vasodilation and the inability to offset 
sympathetic vasoconstrictor tone during exercise is in part due to diminished endogenous 
levels of circulating ATP in aging humans.  On the whole, ATP appears to be a 
significant regulator of vascular control in humans, and may act as a potential mechanism 
which in part explains the typically observed reductions in skeletal muscle blood flow 
and oxygen delivery to active tissue in aged humans thereby predisposing thi  population 
to an elevated risk for cardiovascular diseases, age-related declines in exercise 
capacity/tolerance, and an overall decline in quality of life in this population. 
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CHAPTER I – INTRODUCTION/ EXPERIMENTAL AIMS 
 
Blood flow through a muscle vascular bed is primarily determined by means of 
the arteriovenous pressure difference across that bed (∆P = Pa - Pv) and its vascular 
conductance (VC), (Qa = ∆P x VC, where Qa is arterial inflow).  Therefore, adjustments 
in perfusion pressure or vascular tone could act together or independently as possible 
blood flow regulating mechanisms.  In quiescent skeletal muscle under stable perfusion 
pressure gradients, blood flow is chiefly determined by the vascular tone of artrioles.  
Specifically, vascular conductance is directly proportional to the radius of thevess l 
raised to the fourth power and is inversely proportional to the length of the vessel and to 
the viscosity of the fluid through the vessel.  On the other hand, the pressure gradient 
across a muscle bed is determined by the difference between arterial luminal pressure and 
a critical downstream 'back-pressure', which is commonly thought to be venous luminal 
pressure.  Thus, blood flow could be augmented via changes in the perfusion pressure 
gradient, either by increases in arterial pressure or by reductions in venous pressure.  
Nonetheless, adjustments in either vascular tone or perfusion pressure can have profound 
independent effects on muscle blood flow.  
During whole body exercise, both changes in perfusion pressure and vessel caliber 
occur, thus concomitantly assisting in the elevation of blood flow and oxygen delivery to 
match the metabolic demand of the active tissue without compromising blood pressure.  
Accordingly, the local control of vascular tone during exercise consists of a fine interplay
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between sympathetic neural vasoconstriction and local metabolic vasodilation, and 
together dictates optimal blood flow and oxygen delivery to the active tissue.  For over a
century, experiments have been directed towards increasing our understanding of the 
factors that regulate vascular tone during exercise.  Although it is clear that 
vasoconstriction occurs in both inactive and active tissue via elevations in sympathetic 
nervous system activity, the substances evoking vasodilation during exercise are 
somewhat more perplexing.  To date, it has been difficult to identify any one singlfactor 
that is obligatory to observe exercise hyperemia in humans, although many vasodilators 
are recognized to contribute (adenosine, nitric oxide, vasodilating prostaglandins, K+).  
Nonetheless, we have recently turned our attention the postulate that circulating 
nucleotides have an explicit role in the control of vascular tone at rest and during 
exercise.  
Importantly, the study of ATP in vascular control has physiological relevanc s it 
is understood that ATP is released extracellularly into the human circulation from a large 
host of cells.  As such, in vitro evidence indicates that circulating ATP may result from 
deoxygenation and mechanical strain upon endothelial cells as well as erythrocytes and 
platelets, although other cells are recognized to have this ability as well.  For many 
decades, nucleotides have been recognized to reside within the circulation of humansand 
to have robust vasodilator action when infused intra-arterially.  More recently, evidence 
indicates that ATP has powerful vasodilatory action in that it can evoke elevations in 
blood flow similar to that observed during maximal exercise and results in the ability to 
significantly blunt (and in some instances abolish) sympathetically-mediated 





exercise in young adults.  In addition, although heavily touted as an endothelium-
dependent vasodilator, ATP appears to evoke vasodilation independent of nitric oxide, 
vasodilating prostaglandins, as well as adenosine, and may chiefly cause vasodilation via 
spreading hyperpolarization (yet unexplored in humans).  Interestingly, these vasomotor 
properties are specific to ATP and are typically not observed with downstream adenine 
nucleotide, AMP, or nucleoside, adenosine. 
With respect to alterations observed with advancing age in humans, it is well 
recognized that aging serves as a primary independent risk factor for the development of 
cardiovascular disease. In particular, older adults demonstrate impaired vasodilation to 
endothelium-dependent stimuli as well as an attenuated increase in blood flow (and 
oxygen delivery) to various metabolic stimuli including exercise.  Moreover, this is 
largely a result of impaired local vasodilation.  As stated above, the endogenous 
circulating nucleotide ATP appears to maintain specific vasomotor properties in young 
adults, yet whether a deficit in either the responsiveness or the circulating content of this 
molecule results with advancing age is unknown. 
  Therefore, this body of work comprises four explicit hypotheses aimed to 
enhance our understanding of the contribution of circulating ATP to vascular control at 
rest and during exercise in humans.  Considerable emphasis is placed upon how this 








Overall hypothesis: ATP has definite vasodilator and sympatholytic vasomotor 
properties in young adults during exercise, but that these actions are impaired in older
adults; and that endogenously circulating levels of ATP are diminished during exercis  in 
the aged population.   
 
Specific Aims 
Experiment #1:  to determine whether exogenous ATP can modulate α- drenergic 
vasoconstriction in the human forearm of young adults. 
 
Experiment #2:  to determine whether vasodilator responsiveness to exogenous ATP is 
impaired in aging humans, and the contribution of adenosine to ATP-mediated 
vasodilation in aging humans. 
 
Experiment #3:  to determine whether the ability of exogenous ATP to modulate α-
adrenergic vasoconstriction in the human forearm of older adults is impaired similar to 
the typical response observed during exercise in aged humans. 
 
Experiment #4:  to determine whether endogenous venous plasma [ATP] and ATP 
release is diminished during mild-to-moderate exercise in aging humans. 
 
To the best of our knowledge, the preceding collection of experiments provides 
novel and significant insight into the understanding of how circulating ATP assists in 





alterations in the contribution of ATP to vascular tone in aging humans exist and may in
part be a potential mechanism by which aged adults have reductions in oxygen delivery 
to active skeletal muscle.  Distinctively, exogenous ATP has the ability to blunt α-
adrenergic vasoconstriction in young adults similar to that observed during exercis .  In 
contrast to our hypothesis, the vasodilatory responsiveness and sympatholytic properties 
of exogenous ATP remain intact in aging humans.  However, older adults demonstrate 
reduced venous plasma [ATP] and impaired ATP release during graded mild-to-oderate 
handgrip exercise which is associated with attenuations in skeletal muscle vasodilation 
and blood flow.  Taken together, it is our belief that the typically observed impairments 
in skeletal muscle vasodilation and the inability to offset sympathetic vasoconstri tor 
tone during exercise is in part due to diminished endogenous levels of circulating ATP.  
On the whole, ATP appears to be a significant regulator of vascular control in humans, 
and may act as a potential mechanism which in part explains the typically observed 
reductions in skeletal muscle blood flow and oxygen delivery to active tissue in aged 
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Recent evidence suggests that adenosine triphosphate (ATP) can inhibit vasoconstrictor 
responses to endogenous noradrenaline release via tyramine in the skeletal muscle 
circulation, similar to what is observed in contracting muscle.  Whether this involves 
direct modulation of postjunctional α-adrenoceptor responsiveness, or is selective for α1- 
or α2-receptors, remains unclear.  Therefore, in Protocol 1, we tested the hypothesis that 
exogenous ATP can blunt direct postjunctional α- drenergic vasoconstriction in humans. 
We measured forearm blood flow (FBF; Doppler ultrasound) and calculated the vascular 
conductance (FVC) responses to local intra-arterial infusions of phenylephrin  (α1-
agonist) and dexmedetomidine (α2-agonist) during moderate rhythmic handgrip exercise 
(15% maximum voluntary contraction), during a control non-exercise vasodilator 
condition (adenosine), and during ATP infusion in 8 young adults.  Forearm hyperaemia 
was matched across all conditions.  Forearm vasoconstrictor responses to direct α1-
receptor stimulation were blunted during exercise vs adenosine (∆FVC = -11±3% vs -
39±5%; P < 0.05), and were abolished during ATP infusion (-3±2%).  Similarly, 
vasoconstrictor responses to α2-receptor stimulation were blunted during exercise vs 
adenosine (-13±4% vs -40±8%; P < 0.05), and were abolished during ATP infusion (-
4±4%).  In Procotol 2 (n = 10), we tested the hypothesis that graded increases in ATP 
would reduce α1-mediated vasoconstriction in a dose-dependent manner compared with 
vasodilatation evoked via adenosine.  Forearm vasoconstrictor responses during low dose 
adenosine (-38±3%) and ATP (-33±2%) were not significantly different from rest (-
40±3%; P > 0.05).  In contrast, vasoconstrictor responses during moderate (-22±6%) and 





responses during adenosine became progressively greater (moderate = -48±4%, P = 0.10; 
high = -53±6%, P < 0.05).  We conclude that exogenous ATP is capable of blunting 
direct postjunctional α-adrenergic vasoconstriction, that this involves both α1- and α2-
receptor subtypes, and that this is graded with ATP concentrations.  Collectively, these 
data are consistent with the conceptual framework regarding how muscle blood flow and 























Blood flow and oxygen delivery increase in proportion to the oxygen demand of 
contracting skeletal muscle, a complex response involving competing influences of local 
vasodilator signals and sympathetic neural vasoconstriction particularly as the intensity of 
exercise and amount of muscle mass engaged increases (Saltin et al. 1998).  Although it 
is clear that sympathetic restraint of active muscle blood flow is imperativ  for 
appropriate blood pressure regulation (Marshall et a . 1961; Rowell, 1997), it has also 
been repeatedly demonstrated that the vasoconstrictor responses in contracting muscle are 
significantly blunted compared with the responses under resting (quiescent) condi ions 
(Remensnyder et al. 1962; Anderson & Faber, 1991; Thomas & Victor, 1998; 
Buckwalter et al. 2001; Tschakovsky ME et al. 2002; Dinenno & Joyner, 2003).  A 
variety of substances/mechanisms have been proposed in this local modulation of 
sympathetic vasoconstriction including activation of ATP-sensitive potassium channels 
(KATP) (Thomas et al. 1997; Keller et al. 2004), adenosine (Nishigaki et al. 1991), nitric 
oxide (NO) (Thomas & Victor, 1998; Chavoshan et al. 2002), and vasodilating 
prostaglandins (PGs) (Faber et al. 1982).  However, recent data indicate that independent 
inhibition of NO and PGs do not influence the ability of contractions to blunt sympathetic 
vasoconstriction (Dinenno & Joyner, 2003, 2004), and that combined inhibition of these 
substances only slightly augments the constrictor response to α-adrenoceptor stimulation 
(Dinenno & Joyner, 2004).  Further, exogenous infusion of adenosine to mimic exercise 
hyperaemia does not blunt sympathetic vasoconstriction (Tschakovsky et al. 2002).  






It has recently been proposed that circulating adenosine triphosphate (ATP) could 
be involved in matching muscle perfusion to oxygen demand during exercise (Ellsworth, 
2000; Gonzalez-Alonso et al. 2002; Ellsworth, 2004).  Although ATP can be produced in 
many cells, one source of ATP release during mismatches in oxygen delivery and 
demand appears to be the red blood cell, where ATP release is coupled with the level of 
deoxygenated hemoglobin (Ellsworth, 2000; Jagger et al. 2001; Gonzalez-Alonso et al. 
2002; Ellsworth, 2004), and can also be augmented by hypercapnia, acidosis, and  
mechanical deformation (Bergfeld & Forrester, 1992; Ellsworth et al. 1995; Sprague t 
al. 1998).  In addition to directly evoking vasodilatation via binding to P2y-receptors on 
the endothelium (Burnstock & Kennedy, 1986; Rongen et al. 1994), work by Rosenmeier 
and colleagues (2004) indicate that ATP could assist in matching oxygen delivery with 
tissue demand by modulating local sympathetic vasoconstrictor tone.  Indeed, data 
derived from this study suggest that circulating ATP can override sympathetic 
vasoconstriction in the leg circulation evoked via intra-arterial administration of tyramine 
(evokes endogenous noradrenaline (NA) release), similar to that observed in contracting 
muscle (Rosenmeier et al. 2004).  This occurred despite similar increases in femoral 
venous NA concentrations, suggesting that this modulatory effect of ATP is at the level 
of postjunctional α-adrenoceptors.  However, it must be emphasized that changes in 
venous NA concentrations do not always accurately reflect NA release from sympathetic 
nerve endings especially when there are marked changes in regional blood flow (Esler et 
al. 1990).  Therefore, whether circulating ATP modulates direct postjunctional α-
adrenoceptor responsiveness and whether this is selective for α1- or α2-adrenoceptors is 





An additional question related to the role of circulating ATP in modulating 
sympathetic vasoconstriction is whether this is graded with the levels of circulating ATP.  
In this context, several studies utilizing isolated limb models have clearly demonstrated 
that the magnitude of sympatholysis during exercise is graded with exercis intensity, 
such that mild levels of muscle contraction (< 10% maximal effort) do not interfere with 
sympathetic vasoconstriction whereas progressive increases in exercis  intensity above 
this level lead eventually to robust blunting of the vasoconstrictor response (Thomas et 
al. 1994; Buckwalter et al. 2001; Tschakovsky et al. 2002; Kirby et al. 2005).  Thus, if 
circulating ATP does indeed play a role in muscle blood flow regulation during 
contractions, one would predict that low levels of ATP are not sympatholytic, whereas 
increasing circulating levels of ATP would lead to a progressive reduction in sympathetic 
vasoconstrictor responsiveness.  This is an important hypothesis to test, as the only data 
regarding how ATP interacts directly with sympathetic vasoconstriction indicates that 
ATP completely overrides the vasoconstrictor response (Rosenmeier et al. 2004).  As 
such, if ATP release from red blood cells occurred in all active muscle during high 
intensity large muscle mass exercise, and this completely abolishes sympathetic 
vasoconstriction as recently demonstrated (Rosenmeier et al. 2004), the vasodilatory 
capacity of exercising muscle would outstrip cardiac pumping capacity and arterial 
pressure would fall (Joyner & Thomas, 2003; Calbet et al. 2004).  In healthy humans, this 
does not occur.       
Therefore, in the present study we tested the hypothesis that exogenous ATP 
infusion blunts direct postjunctional α-adrenergic vasoconstriction in humans and 





ability of muscle contractions to blunt a known sympathetic vasoconstrictor stimulus is 
graded with exercise intensity, we also tested the hypothesis that graded increases in 
arterial ATP concentrations would cause graded inhibition of sympathetic α-adrenergic 




With Institutional Review Board approval and after written informed consent, a 
total of 18 young healthy adults (12 men, 6 women; age = 22 ± 1 years; weight = 72.6 ± 
3.0 kg; height = 176 ± 2 cm; body mass index = 23.1 ± 0.7 kg m-2; means±S.E.M) 
participated in the present study.  All were non-smokers, non-obese, normotensive, and 
not taking any medications.  Studies were performed after a 4-hour fast with the subjects 




 A 20-gauge, 7.6-cm catheter was placed in the brachial artery of the non-
dominant arm under aseptic conditions after local anesthesia (2% lidocaine) for local 
administration of study drugs.  The catheter was connected to a 3-port connector as well 
as a pressure transducer for mean arterial pressure (MAP) measurement and continuously 
flushed at 3 ml h-1 with heparinized saline (Dinenno & Joyner, 2003, 2004; Dinenno t al. 






Forearm Blood Flow and Vascular Conductance 
A 4 MHz pulsed Doppler probe (Model 500V, Multigon Industries, Mt. Vernon, 
NY, USA) was used to measure brachial artery mean blood velocity (MBV) with the 
probe securely fixed to the skin over the brachial artery proximal to the catheter ins rtion 
site as previously described by our laboratory (Dinenno & Joyner, 2003, 2004; Dinenno 
et al. 2005).  The probe insonation angle relative to the skin was 45 degrees. A linear 12 
MHz echo Doppler ultrasound probe (GE Vingmed Ultrasound Vivid7, Horten, Norway) 
was placed in a holder securely fixed to the skin immediately proximal to the velocity 
probe to measure brachial artery diameter.  Forearm blood flow was calculated as: 
FBF = MBV (cm·s-1) * π (brachial artery diameter/2)2 * 60, where the FBF is in 
ml min-1, the MBV is in cm s-1, the brachial diameter is in cm, and 60 is used to convert 
from ml s-1 to ml min-1.  Forearm vascular conductance (FVC) was calculated as 
(FBF/MAP) * 100, and expressed as ml min-1 100 mmHg-1. 
  
Rhythmic Handgrip Exercise 
Maximum voluntary contraction (MVC) was determined for each subject as the 
average of at least three maximal squeezes of a handgrip dynamometer (Stoelting, 
Chicago, IL, USA) that were within 3 percent of each other.  For the exercise t ials, 
weights corresponding to 15% MVC were attached to a pulley system and lifted 4-5 cm 
over the pulley at a duty cycle of 1 s contraction-2 s relaxation (20 contractions per 
minute) using audio and visual signals to ensure the correct timing (Dinenno & Joyner, 





not abolish, sympathetic vasoconstriction in contracting  muscle (Tschakovsky et al. 
2002; Dinenno & Joyner, 2003; Dinenno et al. 2005).   
 
Sympathetic α-Adrenergic Vasoconstrictor Drugs 
 In male subjects, phenylephrine (a selective α1-agonist; Baxter, Irvine, CA) was 
infused at 0.0625 µg (dl forearm volume)-1 min-1 and dexmedetomidine (a selective α2-
agonist; Hospira, Lake Forest, IL) was infused at 6.25 ng (dl forearm volume)-1 in-1.  
The doses of phenylephrine and dexmedetomidine were chosen based on our experience 
at rest (Dinenno et al. 2002; Smith et al. 2007) and during handgrip exercise (Dinenno & 
Joyner, 2003; Rosenmeier t al. 2003a; Dinenno & Joyner, 2004).  Because young 
women typically have reduced vasoconstrictor responses to α-receptor stimulation 
(Kneale et al. 2000), the doses of phenylephrine and dexmedetomidine were doubled for 
the female participants.  All vasoconstrictor drug infusions were adjusted for the 
hyperaemic conditions as previously described (see below) (Dinenno & Joyner, 2003, 
2004).   
Given that exercise increases forearm blood flow, adenosine was infused to 
elevate resting forearm blood flow to similar levels observed during exercise.  We have 
previously demonstrated that exercise blunts the vasoconstrictor responses to dir ct α1- 
and α2-adrenoceptor stimulation, whereas these vasoconstrictor responses are maintained 
when blood flow is elevated with adenosine and hence it was used to create a “high flow” 
control state (Dinenno & Joyner, 2003; Rosenmeier t al. 2003a; Dinenno & Joyner, 
2004).  In an effort to normalise the concentration of each vasoconstricting drug in the 





flow and forearm volume (measured via regional analysis of whole-body DEXA scans).  
Various concentrations of each compound were available to keep the absolute infusion 
rates less than 3 ml min-1 in every trial. 
 
Experimental Protocols 
General Experimental Protocol 
Figure 1 is an example of a time-line for the specific trials.  In the supine position, 
subjects performed either a bout of handgrip exercise, or received intra-arteri l d nosine 
(Sicor, Irvine, CA) or ATP (Sigma, USA); the total time for each trial was 8 minutes.  
After 2 minutes of baseline measurements, exercise or vasodilator infusion was i itiated 
and steady-state FBF was reached within 3 minutes.  Between 3 and 4 minutes of 
hyperaemia (minutes 5 and 6 of Figure 1) the dose of the α1- or α2- agonist 
(vasoconstrictor) was calculated on the basis of forearm volume and blood flow.  The 
vasoconstrictor infusion began at the 6-minute mark and lasted for 2 minutes.    
 
Protocol 1:  Effects of Exogenous ATP on Postjunctional α-adrenergic Vasoconstrictor 
                   Responsiveness 
 The purpose of this protocol was to determine whether exogenous ATP blunts 
direct postjunctional α-adrenergic responsiveness, and whether this is selective for α1- or 
α2-adrenoceptors.  Therefore, in 8 subjects (6 men, 2 women), the vasoconstrictor 
responses to direct α1- and α2-adrenoceptor stimulation (via phenylephrine and 
dexmedetomidine, respectively) were assessed during control vasodilator infusion of 





of ATP.  In total, there were 6 experimental trials for each subject.  In this protocol, the 
goal was to match steady-state FBF during infusion of adenosine or ATP with that 
observed during exercise.  To do so, adenosine (45 nmol 100ml-1 min-1) and ATP (5 nmol 
100ml-1 min1) were initially infused and doses were increased to elevate FBF accordingly.  
The final average doses of adenosine and ATP were 73±8 and 11±2 nmol 100ml-1 min-1, 
respectively.  The order of the adenosine, exercise, and ATP trials were counterbalanced 
across subjects.  Thus, for subjects that did not perform the exercise trial first, we had 
them perform 3-4 minutes of rhythmic handgrip exercise prior to any experimental trials 
with α-agonists to determine their individual steady-state FBF for this exercise intensity.  
Additionally, in one half of the subjects, vasoconstrictor responses to α1-adrenoceptor 
stimulation were determined under each hyperaemic condition, followed by the trials fo  
α2-receptor stimulation.  This order was reversed in the other 4 subjects, and all subjects 
rested for 15 minutes between each trial. 
 
Protocol 2:   Effects of Graded Infusions of ATP on Postjunctional α-adrenergic  
                    Vasoconstrictor Responsiveness  
 The ability of muscle contractions to blunt a known sympathetic vasoconstrictor 
stimulus is graded with exercise intensity, such that greater inhibition of α-mediated 
vasoconstriction (greater sympatholysis) is observed with increasing workloads (Thomas 
et al. 1994; Buckwalter et al. 2001; Tschakovsky et al. 2002; Kirby et al. 2005).  
Therefore, the purpose of this protocol was to determine whether graded increases in 
exogenous ATP caused graded sympatholysis as has been observed during exercise.  In 





adrenoceptor stimulation via phenylephrine at rest (saline control), as well as during 
graded increases in ATP and adenosine.  In total, there were 7 experimental trials for 
each subject and each trial was performed in a similar fashion as outlined in Protocol 1.  
For this protocol, the doses of ATP were calculated (based on resting forearm blood 
flow) to increase arterial concentrations by 500, 1000, and 2000 nmol L-1 (“low”, 
“moderate”, and “high”) provided no ATP degradation were to occur, and this was based 
on data obtained from the femoral vein during graded knee extensor exercise (Gonzalez-
Alonso et al. 2002).  Similar to Protocol 1, we infused adenosine as a control vasodilator 
at concentrations required to match the increase in FBF evoked via these doses of ATP. 
Thus, to do so, ATP trials were always performed prior to adenosine trials, but the order 
of ATP and adenosine doses (low, moderate, and high) were counterbalanced across 
subjects.  All trials were separated by 15 minutes of rest.    
 
Data Acquisition and Analysis 
Data was collected and stored on computer at 250 Hz and analyzed off-line with 
signal-processing software (WinDaq, DATAQ Instruments, Akron, OH, USA).  Mean 
arterial pressure (MAP) was determined from the arterial pressure waveform.  Baseline 
FBF, HR, and MAP represent an average of the last minute of the resting time period, th  
steady-state hyperaemic values represent an average of minutes 3-4 (minutes 5-6 of 
Figure 1; pre-vasoconstrictor) during exercise, adenosine, or ATP and the effects o  the 
α-agonists represent an average of the final 30-seconds of drug infusion (post-
vasoconstrictor).  The % reduction in FBF during vasoconstrictor administration was 





((FBF post constrictor - FBF pre constrictor)/(FBF pre constrictor)) x 100.   
We also calculated % reduction in FVC as our standard index to compare vasoconstrictor 
responses to the α-agonists across conditions, as this appears to be the most appropriate 
way to compare vasoconstrictor responsiveness under conditions where there might be 
differences in vascular tone (Lautt, 1989; O'Leary, 1991; Thomas et al. 1994; 
Tschakovsky et al. 2002).  In an effort to be comprehensive, we have also presented 




All values are reported as means ± S.E.M.  Specific hypothesis testing within each 
of the exercise, adenosine, or ATP trials with the two different α-agonist infusions was 
performed using repeated measures ANOVA.  Comparison of the hemodynamic values at 
specific time points between the exercise, adenosine, and ATP conditions were made 
with unpaired t-tests, and the values within each hyperaemic condition (exercis , 
adenosine, or ATP) with paired t-tests.  Significance was set at P<0.05. 
 
Results 
Protocol 1:  Effects of Exogneous ATP on Postjunctional α-adrenergic Vasoconstrictor 
                   Responsiveness 
Forearm haemodynamics, HR, and MAP for Protocol 1 are presented in Table 1.  
Intra-arterial infusion of both adenosine and ATP, as well as handgrip exercise, 
significantly increased FBF and FVC from baseline (P < 0.05).  As desired by 





ATP infusion were effectively matched to that observed during 15% MVC handgrip 
exercise within both phenylephrine (Figure 2A) and dexmedetomidine conditions (Figure 
2B;  P = 0.5 - 0.9).  Infusion of phenylephrine (α1-agonist) significantly reduced FBF 
from steady-state hyperaemia during adenosine and exercise (P < 0.05), whereas FBF 
was unchanged during ATP (NS; Figure 2A).  Similarly, infusion of dexmedetomidine 
(α2-agonist) significantly reduced FBF from steady-state hyperaemia during adenosine 
and exercise (P < 0.05), whereas FBF was unchanged during ATP (NS; Figure 2B).   
The forearm vasoconstrictor responses to direct α1-adrenoceptor stimulation were 
blunted during steady-state exercise vs adenosine (∆FVC = -11 ± 3% vs -39 ± 5%; P < 
0.05), and were abolished during ATP infusion (-3 ± 2%; P = 0.2 vs zero; Figure 3A).  
Similarly, vasoconstrictor responses to α2-receptor stimulation were blunted during 
exercise vs adenosine (-13 ± 4% vs -40 ± 8%; P < 0.05), and were abolished during ATP 
infusion (-4 ± 4%; P = 0.5 vs zero; Figure 3B).  MAP changed minimally within and 
between conditions (Table 1A and B), thus FBF responses were similar to FVC.  Heart 
rate increased in response to exercise (P < 0.05), but otherwise was not significantly 
between or within trials and conditions (Table 1).   
 
Protocol 2: Effects of Graded Infusions of ATP on Postjunctional α-adrenergic  
                    Vasoconstrictor Responsiveness  
Forearm haemodynamics, HR, and MAP for Protocol 2 are presented in Table 2.  
Graded increases in exogenous ATP evoked a dose-dependent increase in FBF (Figure 
4).  Specifically, increasing the arterial concentration by 500, 1000, and 2000 nmol L-1 





experimental design, steady-state (pre-vasoconstrictor) FBF responses t  adenosine 
infusion were effectively matched to that observed within each dose condition of ATP 
(Figure 4; P = 0.9 - 1.0).  Infusion of phenylephrine (α1-agonist) significantly reduced 
FBF from steady-state hyperaemia during low and moderate dose adenosine ad ATP 
(both P < 0.05; Figure 4A and B).  However, although phenylephrine also reduced FBF 
during high dose adenosine (P < 0.05), it did not significantly affect FBF during high 
dose ATP (P = 0.16; Figure 4C).    
The forearm vasoconstrictor responses to direct α1-adrenoceptor stimulation 
(∆FVC) under control resting conditions were -40 ± 3%.  The vasoconstrictor responses 
during low dose adenosine (-38 ± 3%) and ATP (-33 ± 2%) were not significantly 
different from one another, and were similar to the responses observed at rest (P = 0.3 - 
0.9).   The vasoconstrictor responses during the moderate dose of adenosine tended to be 
greater versus resting conditions (-48 ± 4%; P = 0.07), and the responses during high 
dose adenosine were significantly greater than rest conditions (-53 ± 6%; P < 0.05), most 
likely due to the absolute amount of phenylephrine infused as part of the flow adjustment 
process.  In contrast, the vasoconstrictor responses during moderate dose ATP (-22 ± 6%) 
were significantly blunted compared with rest, and the responses during high dose ATP (-
8 ± 5%) were significantly blunted compared with rest and those observed during low 
dose ATP (both P < 0.05; Figure 5).  Importantly, the vasoconstrictor responses during 
moderate and high dose ATP were significantly blunted compared with the responses 
during the conditions of matched forearm hyperaemia via adenosine (both P < 0.05).  





similar to FVC.  Heart rate and MAP were not significantly different between trials or 
conditions (Table 2). 
 
Discussion 
The primary findings from the present investigation are as follows.  First, 
exogenous infusions of ATP required to match steady-state hyperaemia observed during 
moderate intensity dynamic handgrip exercise (15% MVC) abolishes postjunctional α-
adrenoceptor mediated vasoconstriction in humans.  Second, the ability of ATP to 
modulate α-mediated vasoconstriction under these conditions is not selective for α1-or α2-
adrenoceptors, as both were similarly abolished by exogenous ATP.  Third, increasing 
arterial ATP concentrations to mimic levels observed within the physiological range 
during dynamic exercise elevates resting forearm blood flow in a dose-dependent 
manner.  Finally, low dose ATP infusion is not sympatholytic in the human forearm, 
however graded increases in ATP infusions progressively blunt postjunctional α-
adrenergic vasoconstriction.  Importantly, these data cannot be explained simply by the 
vasodilator properties per se of ATP, as forearm hyperaemia was matched via infusions 
of adenosine which did not blunt sympathetic α-adrenergic vasoconstriction.  The 
physiological implications of these findings will now be discussed.   
 
Exogenous ATP and Postjunctional α-adrenergic Vasoconstriction 
Data derived from experimental studies using a variety of approaches in both 
animals and humans have clearly demonstrated a unique ability of contracting muscle to 





oxygen delivery to active muscle when the sympathetic nervous system is engaged 
(Joyner & Thomas, 2003; VanTeeffelen & Segal, 2003).  Several potential modulators of 
sympathetic vasoconstriction have been suggested to contribute to this phenomenon 
including adenosine, NO, and PGs, although elucidating a clear mechanism in humans 
has proved difficult (Dinenno& Joyner, 2003, 2004).  Recently, however, Rosenmeier 
and colleagues (2004) demonstrated that exogenous ATP infusions abolished regional 
vasoconstriction in the skeletal muscle circulation evoked via intra-arterial tyramine, 
similar to what was observed during isolated knee extensor exercise at 25% ofpeak 
power output.  These data are of significant interest in that infusions of other vasodilators 
such as adenosine and sodium nitroprusside (NO donor) to mimic exercise hyperaemia do 
not interfere with sympathetic vasoconstriction in humans (Tschakovsky et al. 2002; 
Dinenno & Joyner, 2003; Rosenmeier et al. 2003b).  Further, emerging evidence that 
ATP released from red blood cells in proportion to deoxygenated hemoglobin might act 
to couple blood flow and oxygen delivery to demand during exercise make it an attractive 
candidate capable of directly causing vasodilatation and also limiting sympathetic 
vasoconstriction in active muscle.  In this context, ATP appears to be a good candidate 
for explaining sympatholyis because it has a short half-life, is released wh n erythrocytes 
become deoxygenated which would occur in close proximity of active muscle fibers, and 
this would allow sympathetic vasoconstriction to occur in resistance vessels of l s  active 
fibers to maintain an appropriate match between oxygen demand and oxygen delivery at 
the microcirculatory level (Calbet  al. 2006; Lundby et al. 2008). 
In the present study, we directly tested the hypothesis that exogenous ATP 





during exercise.  In the study by Rosenmeier and colleagues (2004), intra-arterial 
administration of tyramine was used to evoke endogenous NA release and cause 
subsequent vasoconstriction.  Although we (Dinenno & Joyner, 2003, 2004) and others 
(Ruble et al. 2002; Wilkins et al. 2006) have also used this approach, it must be 
emphasized that measuring changes in venous NA concentrations do not always 
accurately reflect NA release from sympathetic nerve endings especially when there are 
marked changes in regional blood flow (Esler et al. 1990).  Therefore, we determined the 
forearm vasoconstrictor responses to direct α1- and α2-adrenoceptor simulation (via 
phenylephrine and dexmedetomidine, respectively) during moderate handgrip exercise 
(15% MVC), during control vasodilator infusion of adenosine, and during infusion of 
ATP required to match forearm hyperaemia during exercise (Protocol 1).  As expected, 
there was marked vasoconstriction to both α-agonists during infusion of adenosine, 
whereas the responses were significantly blunted (but not abolished) during handgrip 
exercise.  These data are consistent with our previous work in this area of investigation 
(Dinenno & Joyner, 2003, 2004).  Somewhat similar to our observations during exercise, 
the vasoconstrictor responses to direct α-adrenoceptor stimulation were abolished during 
infusion of exogenous ATP.  To the best of our knowledge, these data provide the first 
experimental evidence that exogenous ATP modulates direct postjunctional α-
adrenoceptor vasoconstriction in humans. 
With respect to the α-adrenoceptor subtypes, we observed no difference in the 
ability of muscle contractions to blunt α1- and α2-mediated vasoconstriction in the human 
forearm.  Similarly, exogenous ATP abolished both α1- and α2-mediated vasoconstriction 





previous studies indicating that both postjunctional α1- and α2-adrenoceptor 
responsiveness are significantly blunted during moderate forearm exercise in humans 
(Dinenno & Joyner, 2003; Rosenmeier et al. 2003a; Dinenno & Joyner, 2004).  It should 
be noted that there are data in humans performing knee extensor exercise suggetive that 
α2-adrenoceptors are more sensitive to metabolic inhibition than α1-receptors (Wray et al. 
2004), and this is conceptually similar with data derived from various experimental 
animal models (Anderson & Faber, 1991; Buckwalter e  al. 2001).  However, in this 
particular study in humans, there were marked pressor effects (and thus baroreflex 
activation) during infusion of the α-agonists that preclude clear interpretation of this data 
(Wray et al. 2004).  Nevertheless, if α2-adrenoceptors are indeed more sensitive to 
metabolic inhibition in the leg circulation, it would be of interest to determine whether 
ATP has a greater modulatory effect on α2- versus α1-adrenoceptor mediated 
vasoconstriction in the leg vasculature.   
  
Exogenous ATP and Graded Modulation of Postjunctional α-adrenergic 
Vasoconstriction  
In Protocol 1, we demonstrated that exogenous ATP required to match steady-
state hyperaemia observed during moderate dynamic handgrip exercise (15% MVC) 
completely abolished postjunctional α1- and α2-mediated vasoconstriction.  From a 
physiological standpoint, however, if circulating ATP were to completely override 
sympathetic vasoconstriction in active muscle during large muscle mass exercis , xcess 
vasodilatation would occur and arterial pressure would be compromised (Marshall et al. 





whether graded ATP infusions evoked a dose-dependent modulation of α-adrenergic 
vasoconstriction, as has been demonstrated during graded levels of exercise (Thomas et 
al. 1994; Buckwalter et al. 2001; Tschakovsky et al. 2002; Kirby et al. 2005).  
Interestingly, we found that low dose ATP infusion (500 nmol L-1) sufficient to increase 
resting forearm blood flow 2-fold did not blunt α-adrenergic vasoconstriction.  This is 
strikingly similar to what is observed during very mild muscle contractions (5% MVC) 
that elevate forearm blood flow to a similar extent (Kirby et al. 2005).  However, at 
moderate (1000 nmol L-1) and higher (2000 nmol L-1) doses of ATP selected to increase 
arterial concentrations similar to that observed in the femoral vein draining skeletal 
muscle during graded knee extensor exercise (Gonzalez-Alonso et al. 2002), α-
adrenoceptor responsiveness was progressively blunted.  In this context, the abiliy of 
graded ATP infusions to limit postjunctional α-adrenoceptor mediated vasoconstriction is 
quite similar to what is observed with graded exercise intensity, and provides further 
support for the hypothesis that circulating ATP could play a significant role in regulating 
muscle blood flow and vascular tone during exercise. 
 
Potential Mechanisms 
The mechanism(s) by which circulating ATP can modulate sympathetic α-
adrenergic vasoconstriction in the skeletal muscle circulation are presently unknown.  
What is clear, however, is that this does not simply reflect the vasodilator propeties of 
ATP per se, as infusions of other vasodilators to mimic exercise hyperaemia do not blunt 
sympathetic vasoconstriction (Tschakovsky et al. 2002; Rosenmeier et al. 2003b).  





adrenergic vasoconstriction.  Thus, we speculate that cellular mechanisms by which 
ATP-induced P2y receptor activation evokes smooth muscle cell relaxation are involved.  
In this context, recent studies indicate that ATP-mediated vasodilatation in humas is 
independent of NO and PGs (van Ginneken et al. 2004), which is consistent with recent 
findings that independent inhibition of NO (Dinenno & Joyner, 2003) and PGs (Hansen  
et al. 2000; Dinenno & Joyner, 2004) do not significantly impact on functional 
sympatholysis in humans.  Further, when we performed combined NO and PG inhibition, 
sympathetic vasoconstriction in contracting muscle was only slightly augmented 
compared with control conditions, suggesting other modulatory factors were involved 
(Dinenno & Joyner, 2004).  Taken together, it seems plausible to speculate that ATP 
evokes smooth muscle cell hyperpolarization, and this in turn blunts sympathetic α-
adrenergic vasoconstriction.  Future studies will be needed to determine the exact 
mechanism underlying the sympatholytic effect of circulating ATP.    
 
Experimental Considerations 
In Protocol 2 of the present investigation, we chose to only use phenylephrine 
(α1- agonist) to test whether the ability of circulating ATP to blunt postjunctional α-
adrenoceptor vasoconstriction was graded with ATP concentrations, as opposed to using 
both α1- and α2-adrenoceptor agonists.  However, in Protocol 1, our data indicated that 
exogenous infusion of ATP at concentrations to match forearm hyperaemia observed 
during moderate intensity handgrip exercise abolished both α1- and α2-mediated 
vasoconstriction, with no apparent difference between the receptor subtypes.  





experimental trials, as this would significantly increase the risk of α2-adrenoceptor effects 
on the central nervous system (e.g., hypotension, sedation).  This is important not only 
from a subject safety standpoint, but also if there were central α2 effects, this would 
inhibit basal sympathetic outflow (Lang et al. 1997) and cloud interpretation of the data 
for the remaining experimental trials .  
An additional consideration for Protocol 2 relates to the dose adjustment of 
phenylephrine we employed based on changes in forearm blood flow, which was 
performed to reduce any potential “dilution effect” of the α1-agonist during the various 
doses of adenosine and ATP.  Our findings indicate that the vasoconstrictor responses 
during the moderate dose of adenosine tended to be greater, and that the vasoconstrictor 
responses during the high dose of adenosine were greater compared with control (saline) 
conditions.  Although seemingly counterintuitive, this is consistent with what has been 
demonstrated when adjustments in the dose of tyramine were performed for simila  
reasons during hyperaemic conditions associated with adenosine infusions (Tschakovsky 
et al. 2002).  Thus, although we were aware this might occur, we needed to be sure that 
any apparent sympatholytic effect of exogenous ATP was not due to a dilution effect, as 
this has never been determined before during ATP infusions.  Regardless, our data clearly 
indicate a graded sympatholytic effect of exogenous ATP whether compared with the 
vasoconstriction observed during control conditions, or conditions of matched 









One limitation of the present study relates to the use of moderate intensity 
exercise with a small muscle mass, and thus moderate hyperaemic conditions, to test our 
hypotheses.  However, our experimental model allows for moderate intensity dynamic 
muscle contractions to be performed without increasing sympathetic outflow, and allows 
for well-controlled vasoactive drug infusions that do not alter arterial blood pressure and 
thus do not evoke baroreflex-mediated alterations in sympathetic outflow.  This is 
important in that changes in sympathetic nervous system activity would cloud 
interpretation of our vasoconstrictor responses during the α-agonist infusions.  
Nevertheless, it is important to recognize that the potential interaction between ATP and 
sympathetic vasoconstriction during larger muscle mass, higher intensity exercis  could 
be more complex than observed in our studies as indicated by recent data demonstrating 
that some degree of local vasoconstriction is necessary for the precise matching of 
oxygen delivery to oxygen demand under such conditions (Calbet et al. 2006; Lundby et 
al. 2008). 
 Another limitation of the present study relates to the lack of measurement of 
circulating arterial or venous plasma ATP concentrations during the experimental trials.  
In Protocol 1, our goal was to match forearm blood flow to that observed during match 
steady-state exercise hyperaemia, thus we were not concerned with how much exogenous 
ATP was required to achieve this.  However, in Protocol 2, our doses were chosen to 
mimic average increases in ATP concentrations observed in the venous circulation during 
graded knee extensor exercise in humans (Gonzalez-Alonso et al. 2002).  We used data 





occur at the level of the microcirculation and thus venous concentrations would provide a 
better estimate of this.  Using this approach, we were able to demonstrate a 2-4 fold
increase in forearm blood flow across this range of exogenous ATP and further, that 
increasing ATP concentrations within this predicted range caused graded sympatholysis.  
However, it still remains unclear what exact concentrations of ATP at the level of the 
resistance vessel network are ultimately observed during exercise, and thus are 
sympatholytic under these conditions.  A final limitation of the present investigation 
relates to the inability to inhibit P2y-receptors in humans due to the lack of available 
pharmacological agent.  In this context, to definitively determine if ATP is 
mechanistically-linked with the ability of muscle contractions to blunt sympathetic 
vasoconstriction, similar studies will need to be performed before and after P2y-r ceptor 
blockade and demonstrate that muscle contractions are incapable of modulating 
sympathetic vasoconstriction under conditions of P2y-receptor inhibition. 
 
Conclusions 
 The results from the present investigation demonstrate that exogenous ATP 
infusions required to match the hyperaemic responses observed during moderate handgrip
exercise abolish postjunctional α1- and α2-adrenoceptor responsiveness in the human 
forearm.  Importantly, graded increases in arterial concentrations of ATP within the 
physiological range that evoke moderate limb hyperaemia causes graded inhibition of α-
mediated vasoconstriction, such that low levels are not sympatholytic whereas 
progressive reductions in α-adrenoceptor mediated vasoconstriction are observed with 





conceptual framework regarding how muscle blood flow and vascular tone are regulated 
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Adenosine        30 + 4 92 + 3 32 + 4 56 + 3 
Exercise        26 + 4 94 + 3 28 + 4 55 + 4 
ATP        29 + 5 92 + 2 31 + 5 54 + 4 
Pre- 
Phenylephrine 
Adenosine      143 + 16* 93 + 3   156 + 19* 57 + 3 
Exercise      154 + 13* 96 + 3   160 + 12*   60 + 4* 
ATP      138 + 19* 94 + 2   149 + 21* 56 + 3 
Phenylephrine 
Adenosine        89 + 9*†   98 + 3*        92 + 10*† 56 + 3 
Exercise      136 + 12*†‡ 96 + 3        141 + 10*†‡   60 + 3* 
ATP      133 + 19*‡ 93 + 1      143 + 21*‡ 54 + 3 






















Adenosine        27 + 4  95 + 2 28 + 4 53 + 3 
Exercise        30 + 6  92 + 3 33 + 7 54 + 4 
ATP        30 + 6  97 + 2 31 + 6 54 + 3 
Pre-
Dexmedetomidine 
Adenosine      141 + 25*  98 + 3   144 + 25* 54 + 4 
Exercise      150 + 16*  94 + 2   158 + 15*   57 + 4* 
ATP      153 + 20*  95 + 2   162 + 21* 54 + 3 
Dexmedetomidine 
Adenosine     85 + 15*† 101 + 3        84 + 15*† 55 + 3 
Exercise     132 + 12*†‡   95 + 2        136 + 12*†‡   57 + 4* 















































*  P < 0.05 vs baseline within condition; † P < 0.05 vs steady-state (Pre-vasoconstrictor; 
Phenylephrine/Dexmedetomidine) within condition; ‡ P < 0.05 vs adenosine during α-agonist 
infusion.  Forearm vascular conductance was calculated as (forearm blood flow/mean arterial 








Table 2.  Protocol 2 Forearm and Systemic Haemodynamics during Graded Infusions  






















Adenosine 1 21 + 4 86 + 3 25 + 5 58 + 5 
ATP 1 23 + 3 86 + 3 27 + 4 59 + 5 
Baseline 
Adenosine 2 23 + 3 86 + 3 27 + 4 58 + 5 
ATP 2 22 + 3 86 + 3 26 + 4 59 + 4 
 
Adenosine 3 23 + 3 86 + 3 28 + 4 60 + 5 
ATP 3 24 + 3 86 + 3 28 + 4 59 + 5 
 
Adenosine 1  51 + 8* 86 + 3   61 + 9* 60 + 5 
ATP 1  50 + 9* 84 + 3     61 + 12* 58 + 5 
Pre-
Phenylephrine 
Adenosine 2  66 + 9* 87 + 2     77 + 11* 59 + 5 
ATP 2  66 + 9* 86 + 3     78 + 12* 59 + 5 
 
Adenosine 3    90 + 12* 87 + 3              105 + 14* 60 + 5 
ATP 3    88 + 13* 84 + 3    106 + 17* 59 + 5 
 
Adenosine 1    33 + 6*† 88 + 4       38 + 7*† 60 + 5 
ATP 1    35 + 7*† 87 + 3       41 + 9*† 59 + 5 
Phenylephrine 
Adenosine 2       36 + 6*†   90 + 3*       41 + 8*† 59 + 5 
ATP 2      53 + 10*† 88 + 4         62 + 12*† 58 + 5 
 
Adenosine 3       43 + 8*†   90 + 4*         50 + 10*† 60 + 5 















































*  P < 0.05 vs baseline within condition; † P < 0.05 vs steady-state (Pre-vasoconstrictor; 
Phenylephrine) within condition; ‡ P < 0.05 vs adenosine during phenylephrine (α1-agonist) 
infusion.  1 = Low dose condition; 2 = Moderate dose condition; 3 = High dose condition (see 
text for details).  Forearm vascular conductance was calculated as (forearm blood flow/mean 


























Figure 1:  General Experimental Trial.  Each trial consisted of a 2-minute baseline period.  
After this time period, subjects either began rhythmic handgrip exercise or received intra-arterial 
adenosine or adenosine triphosphate (ATP) to elevate resting forearm blood flow to levels 
observed during exercise.  During minutes 5-6 (pre-constrictor), the doses of the α1- or α2-
adrenoceptor agonists (phenylephrine or dexmedetomidine, respectively) were calculated on the 
basis of steady-state hyperaemic forearm blood flow and forearm volume.  Subsequently, the α-
agonist was infused for 2 minutes until minute 8. An average of forearm blood flow and mea 
arterial blood pressure during the final 30 seconds of α-agonist infusion was used to calculate the 
vasoconstrictor effect during all hyperaemic conditions.    
Figure 2:  Forearm blood flow at rest, during each hyperaemic condition, and during 
infusion of α-agonists.  Steady-state hyperaemia was similar during rhythmic handgrip exercise, 
adenosine, and ATP infusions for trials involving the α1-agonist phenylephrine (A; Pre-PE) and 
the α2-agonist dexmedetomidine (B; Pre-Dex).  Forearm blood flow was reduced significantly 
with both α-agonists during adenosine and exercise, but the response was attenuated during 
exercise.  In contrast, α-agonist infusion did not significantly reduce forearm blood flow during 
ATP. * P < 0.05 vs steady state (Pre-vasoconstrictor; PE/Dex) within condition; † P < 0.05 vs 
adenosine during α-agonist infusion.  
 
Figure 3:  Forearm vasoconstrictor responses to α1- and α2-adrenoceptor stimulation.  
Percentage reductions in forearm vascular conductance to phenylephrine (α1-agonist) (A) were 
significantly blunted during exercise and abolished during ATP compared with adenosine 
infusions. Similar data was obtained in response to α2-adrenoceptor stimulation via 
dexmedetomidine (B). * P < 0.05 vs adenosine; † P < 0.05 vs zero. 
Figure 4:  Forearm blood flow at rest, during the adenosine and ATP hyperaemic 
conditions, and during infusion of the α1-agonist.  Forearm blood flow was significantly 
elevated in a dose-dependent manner with exogenous ATP (P < 0.05), and forearm 
hyperaemia was effectively matched via infusion of adenosine.  α1-adrenoceptor stimulation 
with phenylephrine (PE) significantly reduced forearm blood flow during all doses (low, 
moderate, high) of adenosine.  In contrast, phenylephrine significantly reduced forearm 
blood flow during low and moderate dose ATP, whereas this was not significant during high 
dose ATP. * P < 0.05 vs steady state (Pre-PE) within condition; † P < 0.05 vs adenosine 
during phenylephrine. 
 
Figure 5:  Forearm vasoconstrictor responses to α1-adrenoceptor stimulation.  
Percentage reduction in forearm vascular conductance in response to α1-adrenoceptor 
stimulation (via phenylephrine; PE) during low dose infusion of adenosine and ATP were 
not significantly different than during saline (control) conditions. α1-mediated 
vasoconstriction was greater during high dose infusion of adenosine compared with 
control, whereas the vasoconstrictor responses were blunted during moderate and high 
dose ATP.  * P < 0.05 vs saline (control); † P < 0.05 vs adenosine within dose condition; 
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The innermost lining of a blood vessel (endothelium) is important for increasing vessel
diameter and facilitating increases in blood flow and oxygen delivery to muscle.  This 
process is typically impaired in older adults.  We demonstrate that increases in blood 
flow to the naturally circulating vessel relaxant, ATP, are intact in older adults who have 
an impaired innermost lining of muscle blood vessels.  Our results show that an 
unhealthy endothelium does not always translate to an inability to relax blood vessels and 
aids in the overall understanding of how blood vessels control oxygen delivery to muscle 




















Endothelium-dependent vasodilatation is reduced with advancing age in humans, as 
evidenced by blunted vasodilator responsiveness to acetylcholine (ACH).  Circulating 
adenosine triphosphate (ATP) has been implicated in the control of skeletal muscle 
vascular tone during mismatches in oxygen delivery and demand (e.g., exercise) via 
binding to purinergic receptors (P2y) on the endothelium evoking subsequent 
vasodilatation, and ageing is typically associated with reductions in muscle blood flow 
under such conditions.  Therefore, we tested the hypothesis that ATP-mediated 
vasodilatation is impaired with age in healthy humans.  We measured forearm blood flow 
(venous occlusion plethysmography) and calculated vascular conductance (FVC) 
responses to local intra-arterial infusions of ACH, ATP, and sodium nitroprusside (SNP)
before and during AA infusion in 13 young and 13 older adults.  The peak increase in 
FVC to ACH was significantly impaired in older compared with young adults (262±71% 
vs 618±97%; P<0.05), and this difference was abolished during AA infusion (510±82% 
vs 556±71%; NS).  In contrast, peak FVC responses were not different between older and 
young adults to either ATP (675±105% vs 734±126%) or SNP (116±111% vs 
1138±148%) and AA infusion did not alter these responses in either age group (both NS).  
In another group of 6 young and 6 older adults, we determined whether vasodilator 
responses to adenosine and ATP were influenced by P1-receptor blockade via 
aminophylline.  The peak FVC responses to adenosine were not different in young 
(350±65%) versus older adults (360±80%), and aminophylline blunted these responses 
by ~50% in both groups.  The peak FVC responses to ATP were again not different in 





group.  Thus, in contrast to the observed impairments in ACH responses, the vasodilatory 
response to exogenous ATP is not reduced with age in healthy humans. Further, our data 
also indicate that adenosine mediated vasodilatation is not reduced with age, and that 

























AA, ascorbic acid; ACH, acetylcholine; ADO, adenosine; ADP, adenosine diphosphate; 
AMP, adenosine monophosphate; APH, aminophylline; ATP, adenosine triphosphate; 
DEXA, dual-energy X-ray absorptiometry; ECG, electrocardiogram; FAV, forearm 
volume; FBF, forearm blood flow; FVC, forearm vascular conductance; HDL, high-
density lipoprotein; HR, heart rate; LDL, low-density lipoprotein; MAP, mean arterial 
pressure; MBV, mean blood velocity; MVC, maximal voluntary contraction; NO, nitric 





















Over the past decade, evidence has begun to point towards the circulating 
endogenous purine nucleotide ATP as having an increasingly important role in vascular 
homeostasis.  As such, circulating ATP is thought to have a role in curtailing platelet 
aggregation (Soslau et al., 1995; Hrafnkelsdottir et al., 2001) and has been implicated in 
the control of skeletal muscle vascular tone during exercise via binding to purinergic 
receptors (P2Y) on the endothelium evoking both considerable vasodilatation and 
attenuating sympathetic vasoconstriction (Gonzalez-Alonso et al., 2002; Kirby et al., 
2008).  In addition, ATP appears to induce vasodilatation primarily via endothelium-
dependent mechanisms and results in spreading vasodilation which has been proposed as 
a significant contributor to the full expression of the exercise hyperemic response (Winter 
& Dora, 2007).  Of note is the fact that other putative endothelium-dependent 
vasodilators such as nitric oxide, prostaglandins, and adenosine do not clearly blunt 
sympathetic vasoconstriction nor evoke spreading dilation, highlighting the unique and 
important properties of ATP (Hoepfl et al., 2002; Winter & Dora, 2007; Kirby et al., 
2008).  Interestingly, the majority of data in young adult humans also suggests that these 
putative vasodilators are not the primary downstream signals by which direct inta-
arterial ATP administration evokes hyperemia (Rongen et al., 1994; van Ginneken et al., 
2004). 
In addition to the aforementioned properties, it is our belief that the contribution 
of circulating ATP to vascular tone in humans is of particular significance from a genuine 
physiological standpoint.  Considerable evidence has mounted demonstrating that the 





‘carrier’, whereby ATP is released from the red cell in direct proportion to the degree of 
hemoglobin deoxygenation (Jagger et al., 2001).  Additionally, ATP is documented to be 
released from endothelial cells into circulation in response to shear stress (a known 
endothelium-dependent stimulus) (Bodin & Burnstock, 1995).  Accordingly, circulating 
endogenous concentrations of ATP increase in young adults during the physiological 
stressors of hypoxia and exercise (Forrester & Lind, 1969; Gonzalez-Alonso et al., 2002).  
Collectively, given the vasomotor properties of ATP and that endogenous [ATP] increase 
in circulation during natural physiological stressors, the responsiveness to thi  proposed 
endothelium-dependent vasodilator in humans may offer substantial insight that is 
unobtainable with the use of other vasodilators whose control of the skeletal muscle 
vasculature during physiological stressors could be questioned.   
With respect to human ageing, advancing age is widely recognized as the primary 
risk factor associated with increased cardiovascular disease risk, and older adults 
typically display characteristics of endothelial cell injury (Celermajer et al., 1994; Lloyd-
Jones et al., 2009).  A normal, healthy endothelium functions to minimize the pro-
inflammatory environment that promotes the initiation and progression of atherosclerotic 
vascular disease.  Further, the endothelial cell layer of the vasculature is significant in 
regulating vasomotor tone, thus facilitating in the balance of blood flow and oxygen 
delivery to the metabolic needs of the tissue (Wu & Thiagarajan, 1996; Vanhoutte, 1997).  
Accordingly, older adults have a blunted responsiveness to endothelium-dependent 
vasodilator stimuli and this endothelial dysfunction contributes to negative alterations in 





During physiological metabolic stress such as exercise, older adults typicall  have 
an attenuated hyperaemic response to exercise which may be mediated via reductions in 
endothelium-dependent vasodilatation (Poole et al., 2003; Proctor & Parker, 2006).  As 
such, we recently demonstrated that acute improvements in endothelial function are 
associated with significant increases in muscle blood flow during dynamic exer ise in 
ageing humans (Kirby et al., 2009).  Importantly, the regulation of blood flow during 
such a stress is a complex response that involves a fine balance between metabolic 
vasodilation and sympathetic vasoconstriction.  In addition to blunted endothelium-
dependent dilation, ageing is also associated with an impaired ability to blunt sympathetic 
vasoconstriction within the active muscle which may limit oxygen delivery to the tissue 
when oxygen requirements are elevated (Koch et al., 2003; Dinenno et al., 2005).  Taken 
together, the control of vascular tone and thus oxygen delivery to skeletal muscle at rest 
and during exercise is impaired in older compared to young adults and is related to 
decrements in overall endothelial health and function. 
  To date, the understanding of vasodilator responsiveness to intra-arterial ATP 
administration in aging humans is not fully understood.  Therefore, we tested the 
hypothesis that ATP-mediated vasodilatation is impaired in older compared with young 
healthy humans.  Additionally, circulating ectonucleotidases (which hydrolyze and 
breakdown ATP toward adenosine) have been suggested to be elevated in disease states 
that are increased with age and who demonstrate endothelial dysfunction (Duarteet al., 
2007; Schetinger et al., 2007; Lunkes et al., 2008).  Given the possibility that ATP could 
be rapidly degraded to its downstream by-products via interactions with circulating 





real impairment to ATP infusion in older adults, in a subgroup of subjects we determined 
ATP-mediated vasodilatation during P1-receptor blockade via aminophylline.  Again, this 
question is of particular importance given that ATP possesses unique vasoactive 
properties (i.e. maximal vasodilator capacity, sympatholysis, and propagated 





With Institutional Review Board approval and after written informed consent, a 
total of 19 young and 19 older healthy adult men and women participated in the present 
study.  All subjects were normotensive and free from overt cardiovascular disese as 
assessed from casual blood pressure measurements and a medical history.  Older subjects 
were further evaluated for clinical evidence of cardiopulmonary disease with a physical 
examination and resting and maximal exercise electrocardiograms.  All subjects were 
sedentary to moderately active, non-smokers, not taking any medications including 
antioxidants, and studies were performed after a minimum of a 4-hour fast.  Subjects 
provided written, informed consent after all potential risks and procedures were 
explained.  This study was approved by the Human Research Committee of Colorado 









A 20-gauge, 7.6-cm catheter was placed in the brachial artery of the non-
dominant arm under aseptic conditions after local anesthesia (2% lidocaine) for local 
administration of study drugs.  The catheter was connected to a 3-port connector as well 
as a pressure transducer for mean arterial pressure (MAP) measurement and continuously 
flushed at 3 ml h-1 with heparinized saline.  The two side ports were used for infusions of 
vasoactive drugs (Kirby et al., 2008; Kirby et al., 2009). 
 
Blood Samples 
 Measures of total cholesterol, low- and high-density lipoproteins (LDL and HDL), 
and triglycerides were performed via conventional methods by the clinical laboratory of 
the Poudre Valley Hospital (Fort Collins, CO, USA).  Oxidized-LDL was measur d via 
standard ELISA (Mercodia, Inc., Uppsala, Sweden) as a marker of circulating oxidative 
stress via the General Clinical Research Center of the Milton S. Hershey Medical Center 
(Hershey, PA, USA).   
 
Body Composition and Forearm Volume 
Body composition was determined by dual-energy X-ray absorptiometry (DEXA; 
Hologic, Inc; Bedford, MA, USA).  Total forearm volume was calculated from regional 
analysis of the experimental forearm (from the proximal to distal radioulnar joint) from 
whole-body DEXA scans with QDR series software for normalization of individual dr g 







Forearm Blood Flow and Vascular Conductance 
Forearm blood flow (FBF) was measured via venous occlusion plethysmography 
using mercury-in-salistic strain gauges (Greenfield et al., 1963; Dinenno et al., 2002).  A 
paediatric blood pressure cuff was placed around the wrist of the experimental arm and 
inflated to suprasystolic pressure (~200 mmHg) to arrest the hand circulation.  
Additionally, a venous occlusion cuff was placed around the upper portion of the 
experimental arm and cycled between rapid inflation at ~50 mmHg (7 seconds) and 
deflation (8 seconds) yielding one blood flow measurement every 15 seconds.  FBF was 
expressed as millilitres per 100 millilitres of tissue per minute (ml (100 ml)-1 in-1).  As 
an index of forearm vasodilatation and to account for individual differences in baseline 
vascular tone, forearm vascular conductance (FVC) was calculated as (FBF/MAP) x 100 
expressed as ml min-1 (100mmHg)-1.  In an effort to minimize the contribution of 
cutaneous blood flow to FBF measurements, a fan was directed at the experimental arm 
throughout the experimental protocol.   
 
Vasoactive Drug Administration 
As a standard test of endothelium-dependent vasodilatation, the muscarinic 
receptor agonist acetylcholine (ACH; Miochol-E, Novartis Inc.) was infused via brachial 
artery catheter at 1, 4, 8, and, 16 µg 100 ml-1 forearm volume min-1 for 4 minutes each.  
Additionally, endothelium-independent vasodilatation was assessed via intra-arteri l 
infusion of sodium nitroprusside (SNP; Nitropress, Hospira Inc.) at 0.25, 0.5, 1, and 2 µg 





2002).  To test our primary hypothesis, the P2Y receptor agonist adenosine triphosphate 
(ATP; Sigma A7699) was infused at 1.25, 2.5, 5, and 10 µg 100 ml forearm volume-1 
min-1 for 4 minutes each (Rongen t al., 1994; Kirby et al., 2008).  ATP was confirmed 
sterile and free of endotoxin with a standard microbiology report (JCB-Analytical 
Research Labs) (Kirby et al., 2008).  As a method of acutely improving endothelium-
dependent vasodilatation, the potent antioxidant ascorbic acid (Vitamin C; American 
Regent Inc.) was infused at 8 mg 100 ml forearm volume-1 in-1 for 10 minutes as a 
loading dose (see Experimental Protocol below), and at 40% of this loading dose for 
maintenance infusion throughout the remainder of the experiment (Taddei et al., 2001; 
Kirby et al., 2009).   
In a second group of subjects, adenosine (Sicor, Irvine, CA) was infused at 3.125, 
6.25, and 12.5 µg 100 ml forearm volume-1 min-1 for 4 minutes as described by Martin 
and colleagues (Martin et al., 2006).  In an effort to produce vasodilatation of a similar 
magnitude as adenosine, the doses of ATP were estimated to be 1.25, 2.5, and 5 µg 100 
ml forearm volume-1 min-1 for 4 minutes based on data from the first group of subjects.  
The P1-receptor blocker, aminophylline (American Reagent, Shirley, NY), was infused 
for 20 minutes at 100 µg 100 ml forearm volume-1 min-1 prior to experimental trials and 
continued through the remainder of the study (Leuenberger t al., 1999; Martin et al., 
2006).  Pilot data in our laboratory indicated this dose of aminophylline markedly 









The primary purpose of the main experimental protocol was to determine whether 
ATP-mediated vasodilatation is impaired in older compared with young adults.  A 
secondary purpose of this protocol was to determine whether ATP-mediated 
vasodilatation would be improved in older adults by acute antioxidant administration of 
AA similar to that observed previously to ACH (Taddei et al., 2001; Kirby et al., 2009).  
Thirteen young (eight men; five women) and thirteen older (eight men; five women) were 
studied in the supine position with the experimental (non-dominant) arm abducted 90º 
laterally at heart level.  The most distal portion of the arm was slightly elevat d in order 
to facilitate venous return during blood flow measurements with venous occlusion 
plethysmography.  After a minimum of 30 minutes following catheterization and 
experimental set-up, the first of three vasoactive drugs (ACH, SNP, or ATP) was infused 
for 4 minutes at each dose totaling 16 minutes of infusion time.  Four minutes of quiet 
rest preceded all vasodilator trials where baseline measurements were performed and 
saline was infused.  Twenty minutes of quiet rest was allotted between all trials and the 
order of vasodilator drug infusion was randomized and counterbalanced across subjects. 
After completion of these initial trials, ascorbic acid was infused at the loading dose for 
10 minutes, then reduced to 40% of this dose for the remainder of the study.  The 
infusions of ACH, SNP, and ACH were then repeated in the same order as before AA for 
each subject.   
In a second experimental protocol in an additional 6 young (4 men; 2 women) and 
6 older (3 men; 3 women) subjects, we determined whether adenosine-mediated 





ATP-mediated vasodilatation could be attributed to greater breakdown to adenosine and 
subsequent P1-receptor stimulation.  Therefore, in randomized and counterbalanced 
fashion, adenosine and ATP were infused before and after local P1-receptor inhibition via 
aminophylline.  The timeline for this protocol was similar to that described above for the 
primary experimental protocol. 
   
Data Acquisition and Analysis 
Data was collected and stored on computer at 250 Hz and analyzed off-line with 
signal-processing software (WinDaq, DATAQ Instruments, Akron, OH, USA).  FBFwas 
determined from the derivative of the forearm plethysmogram.  Mean arterial pressure 
(MAP) was determined from the arterial pressure waveform and heart rate (HR) was 
determined via standard 3-lead ECG.  Baseline FBF, FVC, HR, and MAP represent an 
average of the last minute of the resting time period prior to all pharmacological 
vasodilatory tests.  In addition, all haemodynamic responses from drug infusions 
represent an average of the last minute of data from that specific dose of infusin.  The % 
change in FBF and FVC during drug infusions was calculated as:  
((FBF drug - FBF baseline)/(FBF baseline)) x 100.   
Changes in FVC were calculated in a similar fashion. 
 
Statistics 
All values are reported as means ± S.E.M.  Comparison of subject characteristics 
and the haemodynamic values at specific time points between groups were made with 





tests.  Specific hypothesis testing within trials was performed to assess mean group 
differences between young and older adults using two-way repeated measures analysis of 
variance.  Post-hoc analysis was performed using the Tukey’s test when significance was 
observed.  Significance was set at P<0.05. 
 
Results 
Subject Characteristics  
The mean age difference in age between young and older subjects was ~45 years 
(Table 1).  There were no significant differences between young and older adults in 
forearm volume, HDL-cholesterol, or triglycerides.  Older adults had a greater BMI, body 
fat percentage, total cholesterol, and LDL-cholesterol (all P<0.05), although these values 
were within normal levels.  Baseline FBF, FVC, and HR for all trials were not different 
between young and older adults. Although normotensive, MAP was elevated in older 
compared with young adults (P<0.05).  
 
Vasodilator Drug Administration: Effect of Age  
The vasodilatory responses expressed as the percentage increase in FVC from 
baseline during all doses of ACH, ATP, and SNP are shown in Figure 1A-C.  As 
expected, older adults demonstrated an impaired vasodilatory response to ACH compared 
to that observed in young adults (Figure 1A; P<0.05).  The vasodilatory response to the 
endothelium-independent vasodilator, SNP, was not affected by age (Figure 1C).  In 
contrast to our hypothesis, older adults had a preserved vasodilator response to ATP 





conditions (Table 2).  Within both age groups, MAP was unchanged during ACH and 
ATP, however at the highest 2 doses of SNP, MAP was significantly lower than baseline 
(P<0.05; Table 2).  Similarly, HR was not different between or within ACH and ATP 
infusion, yet the 2 highest doses of SNP resulted in elevated HR compared to baseline for 
both age groups (P<0.05; Table 2).   
 
Vasodilator Drug Administration: Effect of Ascorbic Acid 
Acute infusion of AA restored endothelium-dependent vasodilatation to ACH in 
older adults but had no effect on the dilatory response in young adults (Figure 1A).  In 
contrast, concurrent AA administration during ATP and SNP infusion did not impact the 
vasodilatory responses in either young or older adults (Figure 1B-C).  FBF responses 
followed a similar pattern to that of FVC for all conditions (Table 2).  Neither MAP nor 
HR was significantly affected by administration of AA within any drug condition (P=NS; 
Table 2).   
  
Effect of P1-receptor Blockade on Adenosine- and ATP-mediated Vasodilatation 
 The vasodilatory responses expressed as the percentage increase in FVC from 
baseline during all doses of adenosine and ATP are shown in Figure 2A & 2B.  
Adenosine-mediated vasodilatation was not different between young and older adults at 
any dose (Figure 2A).  Similar to subjects from the primary experiment, vasodiltory 
responsiveness to ATP infusion was again not different between young and older adults 
(Figure 2B).  P1-receptor blockade via aminophylline blunted peak adenosine-mediated 





however had little to no impact on ATP-mediated vasodilatation (~10% vs ~10%; both 
NS vs zero).  Importantly, the effect of aminophylline during either adenosine or ATP 
infusion was not different between age groups (adenosine: P=0.8; ATP: P=0.9, Figures 
2A-B).  FBF responses followed a similar pattern to that of FVC in both age groups and 
within all drug conditions (Table 3).  Neither MAP nor HR was significantly affected 
during ATP or adenosine infusions before or during aminophylline administration 
(P=NS; Table 3). 
 
Plasma Markers of Oxidative Stress 
 At baseline, plasma oxidized-LDL was greater in the older compared with young 
subjects (53±3 vs 39±3 U L-1; P<0.05).  Infusion of ascorbic acid did not affect these 
plasma levels in either young (38±3 U L-1) or older adults (54±3 U L-1), which most 
likely reflects that the ascorbic acid was administered locally via brachial artery catheter 
and was dose-adjusted to forearm volume.  Importantly, the improvements in 
acetylcholine-mediated vasodilatation (see above) in older subjects is consitent with 
prior studies and provides evidence that ascorbic acid was effective at the level of the 
forearm vasculature (Taddei et al., 2001; Kirby et al., 2009). 
 
 Discussion 
 Circulating ATP has been implicated in the control of skeletal muscle vascular 
tone during mismatches in oxygen delivery and demand (e.g., exercise) via binding to 
purinergic receptors on the endothelium, and ageing is typically associated with 





function is observed in aged humans and has been closely related to oxidative stress 
(Taddei et al., 2001; Forstermann & Munzel, 2006; Ashfaq et al., 2008).  The key finding 
of the present investigation is that vasodilator responsiveness to exogenous ATP in 
ageing humans is preserved despite the presence of local endothelial dysfunction as 
evidenced by impaired vasodilatation to acetylcholine infusion.  Further, the presence of 
the antioxidant ascorbic acid reversed the observed impairments to acetylcholine, but had 
no impact on the vasodilatory response to exogenous ATP.  Importantly, the vasodilatory 
response to exogenous ATP was unaffected under conditions of P1-receptor blockade 
(with aminophylline), negating the possibility that adenosine-mediated vasodiltation is, 
in part, masking a genuine diminished vasodilatory response to exogenous ATP.  
Collectively, our findings demonstrate that older adults with endothelial dysfunction 
respond with a similar vasodilatory response to ATP as that observed in young adults. 
 
Ageing and Endothelium-dependent Vasodilatation 
 In older adults, endothelium-dependent vasodilatation in response to ACH 
infusion is attenuated compared to young adults, and this impaired vasodilatory resp nse 
is classically referred to as “endothelial dysfunction” (Yasue et al., 1990).  Despite the 
preponderance of evidence supporting blunted ACH-mediated vasodilatation in older 
adults, data suggests that not all endothelium-dependent agonists demonstrate reduced 
vasodilator responsiveness in aged humans (DeSouza et al., 2002).  Recently, ATP has 
become more recognized as a significant endogenous circulating modulator of vascular 
tone that affects oxygen delivery to meet the metabolic demand of active tissue 





indicate that vasodilatation to ATP is largely dependent on the presence of a healthy
endothelium (Busse t al., 1988; Winter & Dora, 2007).  Therefore, the primary purpose 
of the present experiment was to test the hypothesis that the vasodilatory response to 
exogenous infusion of ATP is impaired in ageing humans.  As expected, healthy older 
adults demonstrated obvious blunted endothelium-dependent vasodilatation in response 
to the muscarinic agonist, ACH, and unaltered vasodilatation to the endothelium-
independent dilator, SNP, compared with young adults.  However, in contrast to our 
hypothesis, no age-associated decrement in ATP-mediated vasodilatation (in the same 
subjects that demonstrated blunted ACH responses) was observed.   
 To the best of our knowledge, only one other group has attempted to determine 
ATP-mediated vasodilatory responsiveness in healthy ageing humans (Imaizumi et al., 
1990).  Similar to the present study, ATP-mediated vasodilatation was not attenuated i 
older subjects (age 57 ± 1 yrs).  However, the findings from this previous study were 
difficult to interpret given that vasodilatation to ACH was not impaired with age (i.e. 
endothelial dysfunction was not present).  Although there is limited direct information in 
healthy aging humans, there appears to be a fairly robust vasodilator response to intra-
coronary artery infusion of ATP in coronary artery diseased patients, a populati n which 
typically exhibits endothelial dysfunction (Takase et al., 1998).  Interestingly, ACH 
infusion in this population often results in vasoconstriction or profoundly weak 
vasodilatation further supporting different vasodilator responses between the 
endothelium-dependent agonists ACH and ATP (Vita et l., 1990; Yasue et al., 1990).  





ATP is not impaired in older adults demonstrating typical ‘endothelial dysfunction’ as 
evidenced by substantially blunted responses to ACH. 
 Classically, age-associated endothelial dysfunction is characterized by a 
functional loss of bioavailable NO (Herrera et al., 2009).  Our laboratory and others have 
demonstrated that acute intra-arterial administration of ascorbic acid can abolish age-
associated impairments in endothelium-dependent vasodilatation to ACH (Taddei et al., 
2001; Kirby et al., 2009).  As such, we anticipated vasodilatation to ATP would be 
impaired in older adults and that we would acutely restore endothelial health with 
ascorbic acid similar to ACH.  In contrast to our hypothesis, ATP-mediated 
vasodilatation was not impaired, thus predictably AA had no effect on ATP vasodilator 
responsiveness.  The majority of studies examining the mechanism by which AA can 
modulate blood flow indicate an ability of AA to scavenge superoxide or stabilize 
tetrahydrobiopterin; both which would preserve the bioavailability of NO (Forstermann 
& Munzel, 2006).  Consequently, the contribution of NO to ACH-mediated 
vasodilatation in aged humans has been shown to be greatly enhanced following AA 
administration (Taddei et al., 1998; Taddei et al., 2001).  In relation to vascular control 
during metabolic stress where circulating ATP has been proposed as particularly 
important, data indicate that AA may be restoring blood flow in older adults via NOS-
mediated pathways (Crecelius et al., 2009; Kirby et al., 2009).  Nonetheless, in the 
present study we did not observe a reduction in vasodilatation to exogenous ATP and this 
was unaffected by AA administration, indirectly supporting previous studies indicating a 
minor contribution of NO to ATP-mediated vasodilatation in humans (Rongen et al., 





 Although in vitro preparations suggest a significant contribution of NO to ATP-
induced vasodilatation (Burnstock, 1990), human data is less convincing.  Rongen and 
colleagues were the first to demonstrate that while NOS blockade can reduce 
vasodilatation to ACH infusion, it does not decrease the vasodilatory response to ATP 
(Rongen et al., 1994).  Following this, multiple other studies including unpublished pilot 
studies from our lab indicate little role for nitric oxide in mediating the vasodilation by 
ATP (Rongen et al., 1994; Shiramoto et al., 1997; Hrafnkelsdottir et al., 2001; van 
Ginneken et al., 2004; Mortensen et al., 2009).  In actuality, clarifying the potential 
downstream vasodilating factors appears to be quite complex even in young people alone 
as investigators have been unable to firmly declare the mechanisms by which ATP results 
in smooth muscle relaxation (van Ginneken et al., 2004).  Most recently, one study in the 
human lower limb suggested that combined blockade of NOS and cycloxygenase may 
blunt some of the ATP-mediated vasodilatation in the human leg, however this study 
could be interpreted differently when calculating % change in vasodilation and is 
somewhat clouded by systemic baroreflex activation (Mortensen et al., 2009).  On the 
other hand, it’s possible the different dose of ATP in these studies could explain the 
contrasted findings (Stanford et al., 2001).  Additionally, keeping in mind that ATP has 
dual vasomotor properties in that it not only results in potent vasodilatation but can also 
blunt vasoconstrictor action; current understanding lends a small role for NO or PG’s in 
the ability to override sympathetic vasoconstriction (Dinenno & Joyner, 2003, 2004).  
Collectively, evidence seems to suggest that downstream signaling of ATP may be more 
closely related to hyperpolarizing factors rather than NO and PGs when initiating 






Ageing and Adenosine-mediated Vasodilatation 
 The finding that vasodilatation to ATP was not different between groups was 
unexpected given the endothelium-dependence of ATP and current knowledge of ACH 
responses in this population.  In this context, we questioned whether ectonucleotidases 
that assist in the breakdown of ATP towards adenosine are elevated in older individuals 
thereby allowing adenosine-mediated vasodilatation to mask any true impairment to 
ATP.  Accordingly, evidence indicates a variety of diseased populations that demonstrate 
endothelial dysfunction exhibit increases in ATP-degrading ectonucleotidases 
presumably as a means to offset inflammatory mediated platelet aggregation by ADP 
(Schetinger et al., 2007; Lunkes et al., 2008).  In particular, ATP hydrolysis is closely 
related to ox-LDL, in which aging humans typically have elevated levels of ox-LDL 
compared to younger adults and was observed in the present study (Duarteet al., 2007).  
Therefore, in a subgroup of subjects we determined adenosine-mediated vasodilatation in 
older adults before and after P1-receptor blockade via aminophylline.  We observed that 
vasodilatation to adenosine infusion was not different in older adults and that the 
contribution of adenosine-mediated vasodilatation during ATP infusion was not 
significant in both young and older adults.  Our findings in aging humans are similar to 
other observations in young adults using adenosine receptor blocking agents (Rongen et 
al., 1994; Mortensen et al., 2009).  Although ectonucleotidase activity in older adults 
under these conditions is not directly known, our observations clearly indicate that 
adenosine-mediated vasodilatation does not appear to mask a true decrement in 






 A few experimental considerations should be acknowledged for the present study.  
First, the ideal method to determine the contribution of ATP to basal vascular tone in 
aging humans would be to use a P2Y receptor antagonist, however the pharmacological 
agents to do this safely in humans is not yet available.  Next, other investigators have 
demonstrated impairments to ACH-mediated vasodilatation yet no attenuated vasodilator 
responsiveness to different endothelium-dependent agonists in ageing individuals 
(DeSouza et al., 2002).  Why this is the case is not clearly known but most likely 
indicates that downstream signaling from muscarinic receptor binding is the most 
prominent age-associated impairment.  Nonetheless, we clearly demonstrate that th
vasodilatory response to ATP infusion was not blunted in the aged group and that this is 
considerably different from what is observed during ACH infusion.   
 Because vasodilatation to ATP was not different between age groups and 
evidence suggests that this population may have increased ectonucleotidase activity 
(Duarte et al., 2007), we aimed to test in a subgroup of adults whether vasodilatation to 
adenosine was masking a true vasodilatory responsiveness to ATP in older adults.  
Therefore, we infused a P1-receptor antagonist during both adenosine and ATP infusions 
and observed ~50% reduction to adenosine-mediated vasodilatation in both age groups 
but a non-significant reduction in vasodilatation during ATP infusions.  Despite our 
attempts to uncover extraneous vasodilatation via the ATP-breakdown product adenosine, 
ADP as well as AMP also results in vasodilatation (Rosenmeier et al., 2008).  Whether 
the balance of nucleotide-mediated vasodilatation is shifted in older adults is difficult to 





endothelium and specific pharmacological antagonists are currently unavailable for 
human use (Ralevic & Burnstock, 1998).  Hence, we were unable to determine the 
contribution of ADP and AMP to exogenous ATP infusion.  Regardless, our data are the 
first clear evidence that adenosine-mediated forearm vasodilatation is not impaired in 
older adults and that vasodilatation via adenosine binding to P1 receptors during ATP 
infusion is minimal in both young and older adults.   
 
Physiological Perspectives 
Exogenous ATP administration can modulate vascular tone in a multifaceted 
manner as a result of evoking both profound dilatation as well as having the ability to 
blunt sympathetic vasoconstriction (Rosenmeier t al., 2004; Gonzalez-Alonso, 2008; 
Kirby et al., 2008).  Thus, from a physiological standpoint, the extent to which ATP is 
present and acts in circulation is of considerable interest.  For many years nucleotides 
have been identified in circulation (Forrester, 1969), however only more recently have 
investigators begun to determine the stimuli that increase [ATP] in blood.  In view of 
this, plasma [ATP] elevate during exercise (Gonzalez-Alonso et al., 2002), and specific 
red blood cell release of ATP is enhanced under conditions of hypoxia, hypercapnia, 
acidosis, and mechanical deformation (Sprague et al., 1996; Ellsworth et al., 2009).  
Despite this understanding in young adults, whether an age-associated impairment in 
circulating [ATP] exists at rest or during various stimuli is uncertain.  Corroborating this 
perspective is the fact that older adults typically demonstrate reduced exercis  and 
hypoxic vasodilatation compared to younger individuals in conditions where ATP would 





al., 1972; Proctor & Parker, 2006; Kirby et al., 2009).  Building upon the present 
observations that vasodilatory responsiveness to exogenous ATP infusion appears intact 
in ageing humans, future work should be aimed at determining whether circulating ATP 
is hampered with age and how this may contribute to altered haemodynamic regulation.   
 
Conclusions 
The findings from the present investigation indicate that vasodilatory 
responsiveness to exogenous ATP is not impaired in ageing humans despite the presence 
of endothelial dysfunction as evidenced by attenuated ACH-mediated vasodilatation.  
Further, adenosine-mediated vasodilatation is intact in older adults and the degradation of 
ATP to adenosine does not appear to ‘mask’ a genuine impairment in endothelium-
dependent vasodilatation to ATP.  Given the physiological relevance of circulating ATP 
to vascular tone, it is plausible that advancing age has little impact on receptor sensitivity 
but results in diminished endogenous release of ATP in circulation.  Taken together, the 
collective observations further emphasize the need to understand downstream vasodilator 













B.S.K contributed to the experimental design, data acquisition, data analysis, data 
interpretation, and drafting of the manuscript.  A.R.C contributed to data acquisition and 
interpretation, and critical review of the manuscript.  W.F.V provided clinical support, 
invasive methodology, and contributed to data acquisition and interpretation, as well as 
critical review of the manuscript.  F.A.D. contributed to the conception and experimental 
design, data acquisition and interpretation, and critical review of the manuscript.  All 
authors approved the final version of the manuscript. 
 
Acknowledgements 
We would like to thank the subjects who volunteered to participate in this study as well 
as Julia Davis for her administrative assistance.  This research was supported by National 



























Ashfaq S, Abramson JL, Jones DP, Rhodes SD, Weintraub WS, Hooper WC, Vaccarino 
V, Alexander RW, Harrison DG & Quyyumi AA. (2008). Endothelial function 
and aminothiol biomarkers of oxidative stress in healthy adults. Hypertension 52, 
80-85. 
 
Bodin P & Burnstock G. (1995). Synergistic effect of acute hypoxia on flow-induced 
release of ATP from cultured endothelial cells. Experientia 51, 256-259. 
 
Burnstock G. (1990). Dual control of local blood flow by purines. Ann N Y Acad Sci 603, 
31-44; discussion 44-35. 
 
Busse R, Ogilvie A & Pohl U. (1988). Vasomotor activity of diadenosine triphosphate 
and diadenosine tetraphosphate in isolated arteries. Am J Physiol 254, H828-832. 
 
Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J & 
Deanfield JE. (1994). Aging is associated with endothelial dysfunction in healthy 
men years before the age-related decline in women. J Am Coll Cardiol 24, 471-
476. 
 
Crecelius AR, Voyles WF, Dumke BR, Davis JA, Kirby BS & Dinenno FA. (2009). 
Improvements in exercise hyperemia via ascorbic acid in older healthy adults: 
role for nitric oxide? FASEB J 777.1, 23. 
 
DeSouza CA, Clevenger CM, Greiner JJ, Smith DT, Hoetzer GL, Shapiro LF & Stauffer 
BL. (2002). Evidence for agonist-specific endothelial vasodilator dysfunction 
with ageing in healthy humans. J Physiol 542, 255-262. 
 
Dinenno FA, Dietz NM & Joyner MJ. (2002). Aging and forearm postjunctional alpha-
adrenergic vasoconstriction in healthy men. Circulation 106, 1349-1354. 
 
Dinenno FA & Joyner MJ. (2003). Blunted sympathetic vasoconstriction in contracting 
skeletal muscle of healthy humans: is nitric oxide obligatory? J Physiol 553, 281-
292. 
 
Dinenno FA & Joyner MJ. (2004). Combined NO and PG inhibition augments alpha-
adrenergic vasoconstriction in contracting human skeletal muscle. Am J Physiol 
Heart Circ Physiol 287, H2576-2584. 
 
Dinenno FA, Masuki S & Joyner MJ. (2005). Impaired modulation of sympathetic α-
adrenergic vasoconstriction in contracting forearm muscle of ageing men. J 






Duarte MM, Loro VL, Rocha JB, Leal DB, Bem AF, Dorneles A, Morsch VM & 
Schetinger MR. (2007). Enzymes that hydrolyze adenine nucleotides of patients 
with hypercholesterolemia and inflammatory processes. FEBS J 274, 2707-2714. 
 
Ellsworth ML. (2004). Red blood cell-derived ATP as a regulator of skeletal muscle 
perfusion. Medicine & Science in Sports & Exercise 36, 35-41. 
 
Ellsworth ML, Ellis CG, Goldman D, Stephenson AH, Dietrich HH & Sprague RS. 
(2009). Erythrocytes: oxygen sensors and modulators of vascular tone. Physiology 
(Bethesda) 24, 107-116. 
 
Forrester T. (1969). The identification of adenosine triphosphate in fresh human plasma. 
J Physiol 200, 53P-54P. 
 
Forrester T & Lind AR. (1969). Identification of adenosine triphosphate in human plasma 
and the concentration in the venous effluent of forearm muscles before, during 
and after sustained contractions. J Physiol 204, 347-364. 
 
Forstermann U & Munzel T. (2006). Endothelial nitric oxide synthase in vascular 
disease: from marvel to menace. Circulation 113, 1708-1714. 
 
Gonzalez-Alonso J. (2008). ATP: a double-edged signalling molecule regulating the flow 
of oxygen. J Physiol 586, 4033-4034. 
 
Gonzalez-Alonso J, Olsen DB & Saltin B. (2002). Erythrocyte and the regulation of 
human skeletal muscle blood flow and oxygen delivery: role of circulating ATP. 
Circ Res 91, 1046-1055. 
 
Greenfield ADM, Whitney RJ & Mowbray JF. (1963). Methods for the investigation of 
peripheral blood flow. British Medical Bulletin 19, 101-109. 
 
Herrera MD, Mingorance C, Rodriguez-Rodriguez R & Alvarez de Sotomayor M. 
(2009). Endothelial dysfunction and aging: An update. Ageing Res Rev. 
 
Hoepfl B, Rodenwaldt B, Pohl U & De Wit C. (2002). EDHF, but not NO or 
prostaglandins, is critical to evoke a conducted dilation upon ACh in hamster 
arterioles. Am J Physiol Heart Circ Physiol 283, H996-H1004. 
 
Hrafnkelsdottir T, Erlinge D & Jern S. (2001). Extracellular nucleotides ATP and UTP 
induce a marked acute release of tissue-type plasminogen activator in vivo in 
man. Thromb Haemost 85, 875-881. 
 
Imaizumi T, Takeshita A, Suzuki S, Yoshida M, Ando S & Nakamura M. (1990). Age-
independent forearm vasodilatation by acetylcholine and adenosine 5'-






Jagger JE, Bateman RM, Ellsworth ML & Ellis CG. (2001). Role of erythrocyte in 
regulating local O2 delivery mediated by hemoglobin oxygenation. American 
Journal of Physiology - Heart & Circulatory Physiology 280, H2833-2839. 
 
Kirby BS, Voyles WF, Carlson RE & Dinenno FA. (2008). Graded sympatholytic effet 
of exogenous ATP on postjunctional alpha-adrenergic vasoconstriction in the 
human forearm: implications for vascular control in contracting muscle. J Physiol 
586, 4305-4316. 
 
Kirby BS, Voyles WF, Simpson CB, Carlson RE, Schrage WG & Dinenno FA. (2009). 
Endothelium-dependent vasodilatation and exercise hyperaemia in ageing 
humans: impact of acute ascorbic acid administration. J Physiol 587, 1989-2003. 
 
Koch DW, Leuenberger U & Proctor DN. (2003). Augmented leg vasoconstricion in 
dynamically exercising older men during acute sympathetic stimulation. J Physiol 
551, 337-344. 
 
Kravec TF, Eggers GW, Jr. & Kettel LJ. (1972). Influence of patient age on forearm and 
systemic vascular response to hypoxaemia. Clin Sci 42, 555-565. 
 
Leuenberger UA, Gray K & Herr MD. (1999). Adenosine contributes to hypoxia-induced 
forearm vasodilation in humans. J Appl Physiol 87, 2218-2224. 
 
Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, 
Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, 
Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, 
Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie 
P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-
Rosett J & Hong Y. (2009). Heart disease and stroke statistics--2009 update: a 
report from the American Heart Association Statistics Committee and Stroke 
Statistics Subcommittee. Circulation 119, 480-486. 
 
Lunkes GI, Lunkes DS, Leal D, Araujo Mdo C, Correa M, Becker L, Rosa CS, Morsch 
VM & Schetinger MR. (2008). Effect of high glucose levels in human platelet 
NTPDase and 5'-nucleotidase activities. Diabetes Res Clin Pract 81, 351-357. 
 
Martin EA, Nicholson WT, Eisenach JH, Charkoudian N & Joyner MJ. (2006). 
Influences of adenosine receptor antagonism on vasodilator responses to 
adenosine and exercise in adenosine responders and nonresponders. J Appl 
Physiol 101, 1678-1684. 
 
Mortensen SP, Gonzalez-Alonso J, Bune LT, Saltin B, Pilegaard H & Hellsten Y. (2009). 
ATP-induced vasodilation and purinergic receptors in the human leg: roles of 
nitric oxide, prostaglandins, and adenosine. Am J Physiol Regul Integr Comp 






Poole JG, Lawrenson L, Kim J, Brown C & Richardson RS. (2003). Vascular and 
metabolic response to cycle exercise in sedentary humans: effect of age. Am J 
Physiol Heart Circ Physiol 284, H1251-1259. 
 
Proctor DN & Parker BA. (2006). Vasodilation and vascular control in contracting 
muscle of the aging human. Microcirculation 13, 315-327. 
 
Ralevic V & Burnstock G. (1998). Receptors for purines and pyrimidines. Pharmacol 
Rev 50, 413-492. 
 
Rongen GA, Smits P & Thien T. (1994). Characterization of ATP-induced vasodilation 
in the human forearm vascular bed. Circulation 90, 1891-1898. 
 
Rosenmeier JB, Hansen J & Gonzalez-Alonso J. (2004). Circulating ATP-induced 
vasodilatation overrides sympathetic vasoconstrictor activity in human skeletal 
muscle. Journal of Physiology 558, 351-365. 
 
Rosenmeier JB, Yegutkin GG & Gonzalez-Alonso J. (2008). Activation of ATP/UTP-
selective receptors increases blood flow and blunts sympathetic vasoconstricti 
in human skeletal muscle. J Physiol 586, 4993-5002. 
 
Schetinger MR, Morsch VM, Bonan CD & Wyse AT. (2007). NTPDase and 5'-
nucleotidase activities in physiological and disease conditions: new perspectives 
for human health. Biofactors 31, 77-98. 
 
Shiramoto M, Imaizumi T, Hirooka Y, Endo T, Namba T, Oyama J, Hironaga K & 
Takeshita A. (1997). Role of nitric oxide towards vasodilator effects of substance 
P and ATP in human forearm vessels. Clin Sci (Lond) 92, 123-131. 
 
Soslau G, McKenzie RJ, Brodsky I & Devlin TM. (1995). Extracellular ATP inhibits 
agonist-induced mobilization of internal calcium in human platelets. Biochim 
Biophys Acta 1268, 73-80. 
 
Sprague RS, Ellsworth ML, Stephenson AH & Lonigro AJ. (1996). ATP: the red blood 
cell link to NO and local control of the pulmonary circulation. American Journal 
of Physiology 271, H2717-2722. 
 
Stanford SJ, Gitlin JM & Mitchell JA. (2001). Identification of two distinct vasodilator 
pathways activated by ATP in the mesenteric bed of the rat. Br J Pharmacol 133, 
825-832. 
 
Taddei S, Galetta F, Virdis A, Ghiadoni L, Salvetti G, Franzoni F, Giusti C & Salvetti A. 
(2000). Physical activity prevents age-related impairment in nitric oxide 






Taddei S, Virdis A, Ghiadoni L, Magagna A & Salvetti A. (1998). Vitamin C improves 
endothelium-dependent vasodilation by restoring nitric oxide activity in essential 
hypertension. Circulation 97, 2222-2229. 
 
Taddei S, Virdis A, Ghiadoni L, Salvetti G, Bernini G, Magagna A & Salvetti A. (2001). 
Age-related reduction of NO availability and oxidative stress in humans. 
Hypertension 38, 274-279. 
 
Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, Satomura K, Ohsuzu F 
& Kurita A. (1998). Endothelium-dependent flow-mediated vasodilation in 
coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 
82, 1535-1539, A1537-1538. 
 
van Ginneken EE, Meijer P, Verkaik N, Smits P & Rongen GA. (2004). ATP-induced 
vasodilation in human skeletal muscle. Br J Pharmacol 141, 842-850. 
 
Vanhoutte PM. (1997). Endothelial dysfunction and atherosclerosis. Eur Heart J 18 
Suppl E, E19-29. 
 
Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, 
Selwyn AP & Ganz P. (1990). Coronary vasomotor response to acetylcholine 
relates to risk factors for coronary artery disease. Circulation 81, 491-497. 
 
Winter P & Dora KA. (2007). Spreading dilatation to luminal perfusion of ATP and UTP 
in rat isolated small mesenteric arteries. J Physiol 582, 335-347. 
 
Wu KK & Thiagarajan P. (1996). Role of endothelium in thrombosis and hemostasis. 
Annu Rev Med 47, 315-331. 
 
Yasue H, Matsuyama K, Matsuyama K, Okumura K, Morikami Y & Ogawa H. (1990). 
Responses of angiographically normal human coronary arteries to intracoronary 
injection of acetylcholine by age and segment. Possible role of early coronary 





















Table 1: Subject Characteristics and Baseline Haemodynamics  
 
Variable Young Older 
   
Male:Female 8:5 8:5 
Age (years) 21 ± 1  66 ± 3* 
Body mass index (kg m-2) 22.0 ± 0.5 24.4 ± 0.9* 
Body fat (%) 17.4 ± 2.1 28.1 ± 2.2* 
Forearm volume (ml) 931 ± 77 876 ± 59 
Total cholesterol (mmol l-1) 3.4 ± 0.2 4.4 ± 0.2* 
LDL cholesterol (mmol l-1) 2.0 ± 0.1 2.9 ± 0.2* 
HDL cholesterol (mmol l-1) 1.2 ± 0.1 1.1 ± 0.1 
Triglycerides (mmol l-1) 0.7 ± 0.1 0.9 ± 0.1 
Mean arterial pressure (mmHg) 85 ± 2 97 ± 2* 
Heart rate (beats min-1) 56 ± 2 57 ± 1 
Forearm blood flow (ml dl FAV-1 min-1) 2.2 ± 0.3 2.0 ± 0.2 
Forearm vascular conductance 
 (ml dl FAV min-1 100 mmHg -1) 
2.7 ± 0.4 2.0 ± 0.2 
 
Data presented as mean ± SEM. LDL = low density lipoprotein; HDL = high density 










FBF = forearm blood flow (ml (100 ml)-1 min-1); MAP = mean arterial pressure (mmHg); HR = heart rate (beats min-1); * P < 0.05 vs 
young; † P < 0.05 vs with AA; note: all absolute MAP values for older adults are significantly greater than young. 
Table 2 
BASELINE DOSE 1 DOSE 2 DOSE 3 DOSE 4 
FBF MAP HR FBF MAP HR FBF MAP HR FBF MAP HR FBF MAP HR 
ACH 


















































































































































































































































































































































































































APH = aminophylline; ADO = adenosine; FBF = forearm blood flow (ml (100 ml)-1 in-1); MAP = mean arterial pressure (mmHg); 
HR = heart rate (beats min-1) 
Table 3 
BASELINE DOSE 1 DOSE 2 DOSE 3 
FBF MAP HR FBF MAP HR FBF MAP HR FBF MAP HR 
ADO 












































































































































































































































































































Figure 1:  Forearm Vasodilatory Responses to Acetylcholine, Adenosine 
Triphosphate, and Sodium Nitroprusside Infusion.  Vasodilatation was significantly 
impaired in older adults during muscarinic receptor agonist infusion (A; ACH) and this 
was abolished during simultaneous AA administration.  There was no significant age-
related impairment in vasodilatation to the purinergic receptor agonist ATP (B) or to the 
NO donor SNP (C), and these responses were unaffected by AA.  * P <0.05 vs young 




















































Figure 2:  Forearm Vasodilatory Responses to Adenosine Triphosphate and Adenosine 
Infusion.  Vasodilatation to P1-receptor agonist adenosine infusion was not significantly 
impaired in older adults (A).  Aminophylline significantly reduced vasodilataton to adenosine 
at all drug doses in both young and older adults.  No significant age-related impairment in 
vasodilatation to the purinergic receptor agonist ATP was observed and this vasodilat ti n was 
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Muscle contractions activate the sympathetic nervous system to assist in blood pressure 
regulation, but also increase blood flow to muscle to support delivery oxygen to the 
active tissue.  A balance between these factors must exist, yet in older adults, this process 
of offsetting the sympathetic control of the vasculature is impaired and may be limited 
blood flow to muscle during exercise.  We recently showed that a circulating factor c lled 
ATP can limit the ability of the sympathetic nervous system to evoke vasoconstri tion in 
young adults, however whether this occurs ineffectively and explains the impairment in 
exercise muscle in older adults is unknown.  We demonstrate that older adults have 
limited ability to increase blood flow during exercise, however this does not result from 

















The ability to modulate α-adrenergic vasoconstriction in contracting muscle is impaired 
with age.  In young adults, adenosine triphosphate (ATP) has been shown to inhibit 
vasoconstrictor responsiveness similar to exercise.  We tested the hypothesis that 
modulation of postjunctional α-adrenergic vasoconstriction to exogenous ATP is 
impaired in aging humans. We measured forearm blood flow (FBF; Doppler ultrasound) 
and calculated vascular conductance (FVC) to intra-arterial infusions of phenylephrine 
(α1-agonist) and dexmedetomidine (α2-agonist) during rhythmic handgrip exercise (15% 
MVC), a control non-exercise vasodilator condition (adenosine), and ATP infusion in 7 
young (22±1) and 7 older (64±3 yrs) adults.  Forearm hyperemia was matched across all 
conditions.  During adenosine, forearm vasoconstrictor responses to direct α1-stimulation 
were lower in older adults (∆FVC= -25±3 vs -41±5%); the responses to α2-stimulation 
were not different (-35±6% vs -44±8%).  The ability to blunt α1- and α2-vasoconstriction 
was impaired in older adults during exercise (α1 = 32±13 vs 74±8%; α2 = 19±8 vs 
60±10%).  In contrast, ATP reduced the vasoconstrictor responses by ~85-90% in both 
age groups.  We conclude that the sympatholytic effect of exogenous ATP is not reduced 
with age, and thus blunted ATP release during exercise may contribute to the impaird 











ADO, adenosine; ADP, adenosine diphosphate; AMP, adenosine monophosphate; ATP, 
adenosine triphosphate; DEX, dexmedetomidine; DEXA, dual-energy X-ray 
absorptiometry; ECG, electrocardiogram; FAV, forearm volume; FBF, forearm blood 
flow; FVC, forearm vascular conductance; HR, heart rate; MAP, mean arterial pressure; 





















Vascular regulation within contracting muscle exhibits a fine interplay between 
local vasodilator and sympathetic neural vasoconstrictor signals, and ultimately dic ates 
blood flow and oxygen delivery to the active tissue.  Moreover, the competition between 
these factors appears to increase with the intensity of exercise and the amount of muscle 
mass engaged (Rowell, 1993; Saltin et al., 1998; Saltin, 2007).  Although some debate 
has existed in the past, collective evidence indicates that vasoconstrictor responses in 
contracting muscle are blunted compared to resting (quiescent) muscle presumably to 
minimize a “blood flow error”, however some degree of sympathetic restraint must occur 
to counteract against large declines in blood pressure (Remensnyder et al., 1962; Rowell, 
1997; Buckwalter & Clifford, 2001).  Indeed, we and others have shown in young adult 
humans that muscle contractions have the ability to blunt sympathetically mediated 
vasoconstriction which is graded with the level of exercise intensity is coupled with the 
metabolic demand of contracting skeletal muscle (Buckwalter et al., 2001; Tschakovsky 
et al., 2002; Kirby et al., 2005) 
In an effort to gain insight into this control of vascular tone, investigations have 
aimed at determining the factor(s) which may consist of such dual vasomotor properties 
distinctively observed within contracting skeletal muscle. While many substances result 
in vasodilation, few have demonstrated the additional capacity to blunt sympathetic 
vasoconstriction; including but not limited to adenosine, vasodilating prostaglandins, 
nitric oxide, and beta-adrenergic receptor stimulation via isoproterenol (Tschakovsky et 
al., 2002; Dinenno & Joyner, 2004)  Nevertheless, we and others have recently 




(Rosenmeier et al., 2004; Kirby et al., 2008).  Further, graded increases in arterial 
concentrations of ATP that evoke moderate limb hyperemia result in graded inhibitio  of 
direct postjunctional alpha stimulation, such that low levels are not sympatholytic where
as progressive reductions in α-adrenergic receptor mediated vasoconstriction are 
observed with increasing [ATP] (Kirby et al., 2008).  This is strikingly similar to the 
intensity dependent sympatholytic nature of muscle contractions.  Importantly, hese 
unique responses appear specific to ATP and are not mediated by its degradation by-
products (ADP, AMP, or adenosine) (Rosenmeier t al., 2008).   
With respect to human aging, which poses an elevated cardiovascular disease risk, 
literature suggests a classic “upregulation-desensitization” response whereby older adults 
have clear elevations in muscle sympathetic nervous system activity yet have diminished 
α-adrenergic receptor responsiveness (Seals & Esler, 2000; Seals & Dinenno, 2004; 
Dinenno & Joyner, 2006).  Although sympathetic vasoconstrictor responses differ 
slightly between upper and lower limbs at rest (Dinenno et al., 2002; Smith et al., 2007) 
general consensus point towards enhanced vasoconstriction and blunted vasodilation to 
imposed stimuli during muscle contractions in older adults compared to young (Seals & 
Dinenno, 2004; Dinenno & Joyner, 2006; Versari et al., 2009).  Therefore, it was recently 
hypothesized that aging is associated with an impaired modulation of α-adrenergic 
vasoconstriction in the vascular beds of contracting muscle (i.e. impaired functional 
sympatholysis).  Accordingly, Dinenno and colleagues demonstrated that this in fact was 
the case and postulated that this impairment may underscore reductions in blood flow and 
oxygen delivery in active muscle, thereby potentially limiting oxygen uptake and exercise 




Despite information in young healthy humans, to date, a coherent understanding 
on the interactions of the vasodilator ATP and α-adrenergic vasoconstrictor stimuli in 
aging humans in unclear.  Therefore, we tested the hypothesis that modulation of 
postjunctional α-adrenergic vasoconstriction to exogenous ATP is impaired in aging 
humans. To do so, we utilized the exact study design as previously described in young 
subjects (Kirby et al., 2008) by measuring forearm hemodynamics (Doppler ultrasound) 
to intra-arterial infusions of phenylephrine (α1-agonist) and dexmedetomidine (α2-
agonist) during rhythmic handgrip exercise (15% MVC), a control non-exercise 
vasodilator condition (adenosine), and ATP infusion in discrete groups of young and 
older adults.  Our findings indicate that the sympatholytic effect of exogenous ATP is not 
reduced with age, and thus we speculate that circulating endogenous concentrations of 
ATP are reduced during exercise in older adults and may contribute to the typically 




With Institutional Review Board approval and after written informed consent, a 
total of 7 older healthy adults (5 men, 2 women; age = 64 ± 2 years; weight = 80 ± 5 kg; 
height = 180 ± 3 cm; body mass index = 25 ± 1 kg m-2; means±S.E.M) participated in the 
present study.  All were non-smokers, non-obese, normotensive, and not taking any 
medications.  Studies were performed after a 4-hour fast with the subjects in the supine 






 A 20-gauge, 7.6-cm catheter was placed in the brachial artery of the non-
dominant arm under aseptic conditions after local anesthesia (2% lidocaine) for local 
administration of study drugs.  The catheter was connected to a 3-port connector as well 
as a pressure transducer for mean arterial pressure (MAP) measurement and continuously 
flushed at 3 ml h-1 with heparinized saline (Kirby et al., 2008).  The two side ports were 
used for infusions of vasoactive drugs. 
 
Forearm Blood Flow and Vascular Conductance 
A 4 MHz pulsed Doppler probe (Model 500V, Multigon Industries, Mt. Vernon, 
NY, USA) was used to measure brachial artery mean blood velocity (MBV) with the 
probe securely fixed to the skin over the brachial artery proximal to the catheter ins rtion 
site as previously described by our laboratory (Kirby et al., 2007; Kirby et al., 2008).  
The probe insonation angle relative to the skin was 45 degrees. A linear 12 MHz echo 
Doppler ultrasound probe (GE Vingmed Ultrasound Vivid7, Horten, Norway) was placed 
in a holder securely fixed to the skin immediately proximal to the velocity probe to 
measure brachial artery diameter.  Forearm blood flow was calculated as: 
FBF = MBV (cm·s-1) * π (brachial artery diameter/2)2 * 60, where the FBF is in 
ml min-1, the MBV is in cm s-1, the brachial diameter is in cm, and 60 is used to convert 
from ml s-1 to ml min-1.  Forearm vascular conductance (FVC) was calculated as 






Rhythmic Handgrip Exercise 
Maximum voluntary contraction (MVC) was determined for each subject as the 
average of at least three maximal squeezes of a handgrip dynamometer (Stoelting, 
Chicago, IL, USA) that were within 3 percent of each other.  For the exercise trial , 
weights corresponding to 15% MVC were attached to a pulley system and lifted 4-5 cm 
over the pulley at a duty cycle of 1 s contraction-2 s relaxation (20 contractions per 
minute) using audio and visual signals to ensure the correct timing (Kirby et al., 2008).  
We chose this moderate workload because it significantly blunts, but does not abolish, 
sympathetic vasoconstriction in contracting muscle (Kirby et al., 2005; Kirby et al., 
2008).   
 
Sympathetic α-Adrenergic Vasoconstrictor Drugs 
 In male subjects, phenylephrine (a selective α1-agonist; Baxter, Irvine, CA) was 
infused at 0.0625 µg (dl forearm volume)-1 min-1 and dexmedetomidine (a selective α2-
agonist; Hospira, Lake Forest, IL) was infused at 6.25 ng (dl forearm volume)-1 in-1.  
The doses of phenylephrine and dexmedetomidine were chosen based on our experience 
at rest and during handgrip exercise.  All vasoconstrictor drug infusions were adjusted for 
the hyperaemic conditions as previously described (see below) (Kirby et al., 2008).   
Given that exercise increases forearm blood flow, adenosine was infused to 
elevate resting forearm blood flow to similar levels observed during exercise.  We have 
previously demonstrated that exercise blunts the vasoconstrictor responses to dir ct α1- 
and α2-adrenoceptor stimulation, whereas these vasoconstrictor responses are maintained 




control state (Tschakovsky et al., 2002; Kirby et al., 2008).  In an effort to normalise the 
concentration of each vasoconstricting drug in the blood perfusing the forearm, the 
infusions were adjusted on the basis of forearm blood flow and forearm volume 
(measured via regional analysis of whole-body DEXA scans).  Various concentrations of 




General Experimental Protocol 
Figure 1 is an example of a time-line for the specific trials.  In the supine position, 
subjects performed either a bout of handgrip exercise, or received intra-arteri l d nosine 
(Sicor, Irvine, CA) or ATP (Sigma, USA); the total time for each trial was 8 minutes.  
After 2 minutes of baseline measurements, exercise or vasodilator infusion was i itiated 
and steady-state FBF was reached within 3 minutes.  Between 3 and 4 minutes of 
hyperaemia (minutes 5 and 6 of Figure 1) the dose of the α1- or α2- agonist 
(vasoconstrictor) was calculated on the basis of forearm volume and blood flow.  The 
vasoconstrictor infusion began at the 6-minute mark and lasted for 2 minutes.    
 
Effects of Exogenous ATP on Postjunctional α-adrenergic Vasoconstrictor 
Responsiveness 
 The purpose of this protocol was to determine whether exogenous ATP blunts 
direct postjunctional α-adrenergic responsiveness in aging humans, and whether this is 




vasoconstrictor responses to direct α1- and α2-adrenoceptor stimulation (via 
phenylephrine and dexmedetomidine, respectively) were assessed during control 
vasodilator infusion of adenosine, during moderate rhythmic handgrip exercise (15% 
MVC), and during infusion of ATP.  In total, there were 6 experimental trials for each 
subject.  In this protocol, the goal was to match steady-state FBF during infusion of 
adenosine or ATP with that observed during exercise.  To do so, adenosine (45 nmol 
100ml-1 min-1) and ATP (5 nmol 100ml-1 min1) were initially infused and doses were 
increased to elevate FBF accordingly.  The final average doses of adenosine and ATP 
were 75±21 and 10±2 nmol 100ml-1 min-1, respectively.  The order of the adenosine, 
exercise, and ATP trials were varied across subjects.  Thus, for subjects that did not 
perform the exercise trial first, we had them perform 3-4 minutes of rhythmic andgrip 
exercise prior to any experimental trials with α-agonists to determine their individual 
steady-state FBF for this exercise intensity.  Additionally, in 4 of the subjects, 
vasoconstrictor responses to α1-adrenoceptor stimulation were determined under each 
hyperaemic condition, followed by the trials for α2-receptor stimulation.  This order was 
reversed in the other 3 subjects, and all subjects rested for 15 minutes between each trial. 
 
Previously Published Results from Young Adults 
 This experimental protocol has been previously published in young adults, 
therefore any reference to young adults refers to this published experiment (Kirby et al., 
2008).  The protocol was exactly replicated in older adults for the present study as in 
young adults, and thus enhances the findings when determining the impact of age on the 




The exact protocol and equipment were emulated and used for data collection and 
analysis.  Because vasoconstrictor responsiveness is not equal between age groups at rest 
in the forearm for a given receptor subtype (Dinenno et al., 2002; Dinenno et al., 2005) 
we calculated the magnitude of sympatholysis as a means of determining the abili y of 
exercise or ATP to blunt alpha receptor stimulation (Dinenno et al., 2005). The percent 
magnitude of sympatholysis was calculated as [(% ∆ FVCconstriction Adenosine  – % ∆ 
FVCconstriction Exercise)/ % ∆ FVCconstriction Adenosine] *100. 
 
Data Acquisition and Analysis 
Data was collected and stored on computer at 250 Hz and analyzed off-line with 
signal-processing software (WinDaq, DATAQ Instruments, Akron, OH, USA).  Mean 
arterial pressure (MAP) was determined from the arterial pressure waveform.  Baseline 
FBF, HR, and MAP represent an average of the last minute of the resting time period, th  
steady-state hyperaemic values represent an average of minutes 3-4 (minutes 5-6 of 
Figure 1; pre-vasoconstrictor) during exercise, adenosine, or ATP and the effects o  the 
α-agonists represent an average of the final 30-seconds of drug infusion (post-
vasoconstrictor).  The % reduction in FBF during vasoconstrictor administration was 
calculated as:  
((FBF post constrictor - FBF pre constrictor)/(FBF pre constrictor)) x 100.   
We also calculated % reduction in FVC as our standard index to compare vasoconstrictor 
responses to the α-agonists across conditions, as this appears to be the most appropriate 
way to compare vasoconstrictor responsiveness under conditions where there might be 




effort to be comprehensive, we have also presented absolute values of forearm 




All values are reported as means ± S.E.M.  Specific hypothesis testing within each 
of the exercise, adenosine, or ATP trials with the two different α-agonist infusions was 
performed using repeated measures ANOVA.  Comparison of the hemodynamic values at 
specific time points between the exercise, adenosine, and ATP conditions were made 
with unpaired t-tests, and the values within each hyperaemic condition (exercis , 
adenosine, or ATP) with paired t-tests.  Significance was set at P<0.05. 
 
Results 
Effects of Exogneous ATP on Postjunctional α-adrenergic Vasoconstrictor 
Responsiveness in Older adults 
Forearm haemodynamics, HR, and MAP for are presented in Tables 2A & B.  
Intra-arterial infusion of both adenosine and ATP, as well as handgrip exercise, 
significantly increased FBF and FVC from baseline (P<0.05).  As desired by 
experimental design, steady-state (pre-vasoconstrictor) FBF responses t  adenosine and 
ATP infusion were effectively matched to that observed during 15% MVC handgrip 
exercise within both phenylephrine (Figure 2A) and dexmedetomidine conditions (Figure 
2B;  P = 0.4 - 0.8).  Infusion of phenylephrine (α1-agonist) significantly reduced FBF 
from steady-state hyperaemia during adenosine and exercise (P < 0.05), whereas FBF 




(α2-agonist) significantly reduced FBF from steady-state hyperaemia during adenosine 
and exercise (P < 0.05), whereas FBF was unchanged during ATP (NS; Figure 2B).   
The forearm vasoconstrictor responses to direct α1-adrenoceptor stimulation were 
blunted during steady-state exercise vs adenosine (∆FVC = -15 ± 2% vs -25 ± 3%; P < 
0.05), and were abolished during ATP infusion (-1 ± 4%; P = 0.8 vs zero; Figure 3A).  
Similarly, vasoconstrictor responses to α2-receptor stimulation were blunted during 
exercise vs adenosine (-26 ± 4% vs -35 ± 8%; P < 0.05), and were abolished during ATP 
infusion (-5 ± 5%; P = 0.3 vs zero; Figure 4A).  MAP changed minimally within and 
between conditions (Tables 2A and B), thus FBF responses were similar to FVC.  Heart 
rate increased in response to exercise during phenylephrine (P < 0.05), but otherwise was 
not different between or within trials and conditions (Tables 2A & B).   
 
Magnitude of Sympatholysis: Impact of Advancing Age 
A comparison between young and older adults of the vasoconstrictor 
responsiveness during handgrip exercise, and intra-arterial infusions of adenosine ad 
ATP are presented in figures 3 & 4.  The ‘magnitude of sympatholysis’ or the ability to 
blunt α-adrenergic vasoconstriction during exercise was significantly blunted in oler 
adults compared to young adults for each receptor subtype (α1 = 32% vs 74%; α2 = 19% 
vs 60%; respectively, Figure 3B & 4B).  In contrast, exogenous ATP appeared to blunt 
vasoconstriction to both α-receptor subtype independent of age (α1 = 94% vs 88%; α2 = 







The primary findings from the present investigation are as follows.  Exogenous 
ATP required to match forearm hyperemia during moderate handgrip exercise aboli hes 
direct postjunctional α-adrenoceptor mediated vasoconstriction in older adults, and this 
involves both α1- and α2-receptor subtypes.  The present data corroborate previous 
findings that at rest in the human forearm, α1-adrenoceptor responsiveness is blunted in 
older adults compared to young while α2-adrenoceptor sensitivity is relatively intact.  As 
expected, aged humans have enhanced vasoconstriction to direct postjunctional α-
adrenergic receptor stimulation during modest intensity forearm exercise, thus 
demonstrating a reduced magnitude of sympatholysis with exercise.  However in contrast 
to our hypothesis, the ability of exogenous ATP to blunt postjunctional α-adrenergic 
vasoconstriction is similar in young and older adults.   
The rationale for the present study stems from the understanding that a 
competition exists between local vasodilator and neural sympathetic vasoconstrict r 
signals during exercise as a means to regulate blood flow and oxygen delivery to active 
skeletal muscle without compromising blood pressure (Rowell, 1997; Buckwalter & 
Clifford, 2001).  As such, it is well recognized that vasodilatation and sympathetic 
activation simultaneously occur with the degree of exercise intensity and muscle mass 
recruited (Rowell, 1997; Saltin et al., 1998).  Although once heavily debated, 
accumulating evidence appears to now indicate that exercise has the ability to lunt 
sympathetic vasoconstriction within the active muscle, presumably as a means of 
defending against a ‘blood flow error’ (Tschakovsky et al., 2002; Dinenno & Joyner, 




al., 1962).  Over the last decade, investigators have placed a substantial amount of effort 
into finding the factor(s) responsible for blunting sympathetic vasoconstriction withi  
active muscle, and appear to have collectively indicated only a minimal role for the
putative vasodilator action of adenosine, nitric oxide, prostaglandins, and beta-adrenergic 
stimulation (Tschakovsky et al., 2002; Dinenno & Joyner, 2004).  Further, it does not 
appear that any physical mechanical effect of muscle contraction explains this 
phenomenon (Kirby et al., 2005).  However, more recently, we and others have 
demonstrated that exogenous ATP has the ability to significantly blunt sympathetic lly-
mediated vasoconstriction in young adults (Rosenmeier et al., 2004; Kirby et al., 2008).  
In addition, given that both circulating ATP levels as well as the ability to blunt
sympathetic vasoconstriction increase in an exercise intensity dependent manner 
(Buckwalter et al., 2001; Gonzalez-Alonso et al., 2002), we had questioned whether this 
response was graded with the dose of ATP infusion, such that low doses of ATP are not 
sympatholytic yet higher doses of ATP produce progressive blunting of constriction 
(Kirby et al., 2008).  This in fact does occur. 
In relation to aging humans, it is well recognized that control of the vasculature is 
altered with advancing age whereby elevations in sympathetic vasoconstrict r activity are 
elevated and vasodilator action is diminished both at rest and during exercise (Dinenno & 
Joyner, 2006; Kirby et al., 2009b).  With specific relevance to the present study, Dinenno 
and colleagues demonstrated that aged men have impaired modulation of sympathetic α-
adrenergic vasoconstriction in contracting muscle (Dinenno et al., 2005) supporting 
previous findings observed in older women (Fadel et a ., 2004) and the leg of older men 




that the sympatholytic properties of exogenous ATP are impaired in aging humans when 
challenged with direct postjunctional α-adrenergic receptor stimulation.  In contrast, we 
observed that the ability of exogenous ATP to blunt sympathetic vasoconstriction is intact 
and is similar between young and older adults.  Despite these responses with exogenous 
ATP, older adults still exhibited an impaired ability to modulate direct α-adrenergic 
constriction during exercise. Collectively, we therefore speculate that the impairment in 
exercise sympatholysis presumably occurs prior to vasodilator signaling via ATP and 
may be a result of attenuated circulating ATP release during exercise in aging humans.   
It has been previously demonstrated that vasoconstrictor responsiveness to α-
adrenergic receptor stimulation in the human forearm at rest is altered in aging humans 
such that α1 but not α2 receptor sensitivity is reduced (Dinenno et al., 2002).  Our 
findings support such a concept and can be seen in Figure 3A & 4A.  Regardless, it is 
clear that despite reduced vasoconstriction to α1 stimulation during adenosine, 
vasoconstriction was significantly blunted during exercise and abolished during ATP in 
older adults.  This discrepant observation between exercise and exogenous ATP 
administration are novel and highlight the unique vasomotor properties of ATP in the 
human circulation.  
As a means of concisely determining the ability of either exercise or exogenous 
ATP to blunt α-adrenergic constriction relative to a control vasodilator (i.e. adenosine), 
we calculated a % magnitude of sympatholysis.  In the present study, we clearly 
demonstrate and support earlier findings that the magnitude of sympatholysis via exercise 
is significantly attenuated in older compared to young adults which are independent of α-




show that the magnitude of sympatholysis via exogenous ATP was similar between 
young and older adults (~90%).  Although these findings may be somewhat surprising 
considering an impaired ability of exercise to blunt sympathetic constriction in aging 
humans, we have recently demonstrated that aging humans have intact vasodilator 
responsiveness to graded doses of exogenous ATP despite clear endothelial dysfunction 
as evidenced by substantial reductions in vasodilation during acetylcholine infusion 
(Kirby et al., 2009a).  Moreover, when comparing the average dose of ATP used in the 
present study (5.6±1 µg/dl FAV/min) in light with our previous findings in young adults 
(6.2±1 µg/dl FAV/min) (Kirby et al., 2008), no significant difference between young and 
older adults is observed. Collectively, these data imply that the dual vasoactive signaling 
properties of ATP are maintained with advancing age in humans.     
 
Potential Mechanisms 
It is important to note that to date, “the” factor(s) directly involved in functional 
sympatholysis have yet to be firmly clarified.  The most promising data supports that 
ATP and UTP (both of which bind to purinergic 2Y receptors along the endothelium) are 
of the few agents currently known to have sympatholytic properties (Rosenmeier et al., 
2008); however whether these substances are obligatory to observe functional 
sympatholysis during muscle contractions cannot currently be directly assessed as no 
receptor antagonist is available for human use.  Further, the specific downstream 
vasodilator mechanisms of ATP also appears to be fraught with unexpected complexity 
even in young adults, as all investigations specifically in the human forearm have 




oxide and vasodilating prostaglandins (Rongen et al., 1994; van Ginneken et al., 2004).  
In addition, it does not appear that degradation of ATP to adenosine underlies ATP-
mediated dilation in young nor older adults and fits with the current theme that adenosine 
is not sympatholytic in nature (Tschakovsky et al., 2002; Kirby et al., 2009a; Mortensen 
et al., 2009).  Studies also show that neither ADP nor AMP blunt sympathetic 
vasoconstriction (Rosenmeier t al., 2008).  Interestingly, ATP and UTP but not 
adenosine evoke endothelium-dependent spreading vasodilation/hyperpolarization that is 
independent of nitric oxide yet inhibited with KCa channel blockade (Winter & Dora, 
2007; Dora, 2010).  When integrating these findings, it is important to note that 
functional sympatholysis and spreading dilation (both of which can result from ATP) 
have been implicated as crucial in optimizing oxygen delivery and blood flow to active 
tissue (Saltin et al., 1998; Dora, 2010).  Whether spreading vasodilation is a fundamental 
component underscoring the phenomenon of functional sympatholysis has yet to be 
determined.  
Another possibility explaining the present observations relates to the endogenous 
release of ATP in human circulation.  Accordingly, evidence indicates that ATP is 
released in young adults in an exercise intensity-dependent manner and is closely re ated 
to changes in the hemoglobin oxygenation, acidosis, as well as mechanical deformation 
of erythrocytes all which occur during muscle contractions (Gonzalez-Alonso et al., 
2002).  We have most recently observed that venous plasma [ATP] and ATP release are 
significantly diminished in older compared to young adults during mild to moderate 
intensity forearm exercise.  As such, we speculate that although both the vasodilatory and 




exercising muscle to modulate sympathetic vasoconstriction with advancing age may be a 
result of reduced endogenous levels of circulating ATP during such a stimulus. 
 
Experimental Considerations 
 It should be considered that we were unable to determine the role of endogenous 
ATP in modulating direct α-adrenergic stimulation during exercise as no pharmacological 
antagonist for the purinergic 2Y receptor is yet available for human use.  In addition, we 
did not measure circulating ATP levels in either group, however this was not the main 
purpose of the study and the population characteristics within the present study are 
similar to our previous report involving ATP measures.  Nonetheless, it is clear that 
exogenous ATP has the ability to blunt sympathetic vasoconstriction in aging humans 
despite an observed impairment of contracting muscle to modulate α-adrenoceptor 
stimulation. 
 Additionally, it is plausible that although vasoconstriction was blunted at this dose 
of exogenous ATP, perhaps a reduced ability to blunt α-adrenergic stimulation could be 
observed at lower ATP doses.  We have previously demonstrated that low ATP doses do 
not evoke sympatholysis yet progressively increasing the ATP dose results in a 
progressive ability to offset the constrictor response (Kirby et al., 2008).  Nevertheless, in 
the present study our dose of ATP was chosen to match the hyperaemic response 
observed during 15% MVC, and at this exercise intensity older adults demonstrate a 







Contracting muscle of aged humans has an impaired ability to modulate 
sympathetic vasoconstriction, and this is not specific to the α-adrenergic receptor 
subtype.  In contrast, the vasodilatory and sympatholytic properties of exogenous ATP 
are intact in older adults, likely indicating that perhaps blunted endogenous ATP release 
during exercise may contribute to the impaired exercise sympatholysis in older adults.  
Collectively, the present findings emphasize the unique vasomotor properties of 
circulating ATP and draw attention to the fact that impaired vasodilation exists in aging 
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TABLE 1: Subject characteristics 
 
________________________________________________________________________ 
                   




Male, Female     5, 2   5, 2                   
  
 Age (years)     22 ± 1              64 ± 2* 
   
 
 BMI (kg·m-2)     23 ± 1              25 ± 1 
 
 Body fat (%)     17 ± 2              19 ± 2 
 
 Forearm volume (ml)    946 ± 25  1104 ± 96 
 
 MVC (kg)     43 ± 2   42 ± 3 
 
 Total cholesterol (mmol l-1)   NA   4.7 ± 0.2 
 
 LDL cholesterol (mmol l-1)   NA   4.2 ± 0.2 
 
 HDL cholesterol (mmol l-1)   NA   1.0 ± 0.1 
 
 Triglycerides (mmol l-1)   NA   1.0 ± 0.1 
________________________________________________________________________ 
MVC = Maximum voluntary contraction, LDL = Low density lipoprotein, HDL = High 
density lipoprotein. * P<0.05 vs. young adults. Note: Young data are adapted from Kirby 








































Adenosine        26 + 4 102 + 4 25 + 4 58 + 3 
Exercise        28 + 5 105 + 4 27 + 5 59 + 4 
ATP        27 + 5 103 + 3 26 + 4 58 + 3 
Pre- 
Phenylephrine 
Adenosine      130 + 23* 107 + 3   123+ 22* 59 + 3 
Exercise      147 + 16* 106 + 4   142 + 17*  62 + 3 
ATP      132 + 23* 105 + 4   132 + 23* 58 + 3 
Phenylephrine 
Adenosine        98 + 17*†  108 + 3        93 + 16*†  60 + 3 
Exercise      126 + 14*†‡ 107 + 4        120 + 16*†‡    63 + 4* 
ATP      129 + 21*‡ 104 + 4      126 + 21*‡  57 + 4  






















Adenosine        25 + 3  103 + 4 25 + 3 61 + 3 
Exercise        25 + 4  104 + 3 24 + 4 61 + 4 
ATP        28 + 5  104 + 4 27 + 5 60 + 3 
Pre-
Dexmedetomidine 
Adenosine      132 + 22*  105 + 4   127 + 22* 60 + 3 
Exercise      149 + 16*  105 + 4   143 + 15* 64 + 4 
ATP      136 + 20*  104 + 3   133 + 21* 60 + 3 
Dexmedetomidine 
Adenosine     82 + 10*†  107 + 4        79 + 11*† 61 + 3 
Exercise     110 + 10*†‡  109 + 4        103 + 10*†‡ 63 + 4 
ATP   132 + 22*‡   105 + 4      128 + 23*‡ 60 + 3 





















Figure 4:  Forearm vascular responses to α2-adrenoceptor stimulation.  (A) The 
vasoconstrictor responses to dexmedetomidine (α2-agonist) were significantly greater in older 
compared with young adults during exercise.  In both groups, the vasoconstrictor responses 
during exercise were blunted, and abolished during ATP compared with adenosine infusions. (B) 
Calculating the ability of exercise to blunt α2-adrenoceptor stimulation demonstrates a significant 
impairment in older compared to young adults, yet (C) no age-associated impairment in the 
sympatholytic properties of ATP was observed.  Forearm vascular conductance was alculated 
as (forearm blood flow/mean arterial pressure) x 100.  The percent magnitude of sympatholysis 
was calculated as [(% ∆ FVCconstriction Adenosine  – % ∆ FVCconstriction Exercise)/  
% ∆ FVCconstriction Adenosine] *100.  * P < 0.05 vs adenosine within age group; † P < 0.05 vs 
young. 
 
Figure 2:  Forearm blood flow at rest, during each hyperaemic condition, and during 
infusion of α-agonists in older adults.  Steady-state hyperaemia was similar during rhythmic 
handgrip exercise, adenosine, and ATP infusions for trials involving the α1-agonist phenylephrine 
(A; Pre-PE) and the α2-agonist dexmedetomidine (B; Pre-Dex).  Forearm blood flow was reduced 
significantly with both α-agonists during adenosine and exercise, but the response was attenuated 
during exercise.  In contrast, α-agonist infusion did not significantly reduce forearm blood flow 
during ATP. * P <0.05 vs steady state (Pre-vasoconstrictor; PE/Dex) within condition; † P < 0.05 
vs adenosine during α-agonist infusion. 
 
Figure 1:  General Experimental Trial.  Each trial consisted of a 2-minute baseline period.  
After this time period, subjects either began rhythmic handgrip exercise or received intra-arterial 
adenosine or adenosine triphosphate (ATP) to elevate resting forearm blood flow to levels 
observed during exercise.  During minutes 5-6 (pre-constrictor), the doses of the α1- or α2-
adrenoceptor agonists (phenylephrine or dexmedetomidine, respectively) were calculated on the 
basis of steady-state hyperaemic forearm blood flow and forearm volume.  Subsequently, the α-
agonist was infused for 2 minutes until minute 8. An average of forearm blood flow and mea 
arterial blood pressure during the final 30 seconds of α-agonist infusion was used to calculate the 
vasoconstrictor effect during all hyperaemic conditions.    
Figure 3:  Forearm vascular responses to α1-adrenoceptor stimulation.  (A) The 
vasoconstrictor responses to phenylephrine (α1-agonist) were significantly blunted in older 
compared with young during passive vasodilatation with adenosine, yet vasoconstricti  was 
greater in older vs young adults during exercise.  In both groups, the vasoconstrictor responses 
during exercise were blunted compared with adenosine, and abolished during ATP infusion. (B) 
Calculating the ability of exercise to blunt α1-adrenoceptor stimulation demonstrates a significant 
impairment in older compared to young adults, yet (C) no age-associated impairment in the 
sympatholytic properties of ATP was observed.  Forearm vascular conductance was alculated as 
(forearm blood flow/mean arterial pressure) x 100.  The percent magnitude of sympatholysis was 
calculated as [(% ∆ FVCconstriction Adenosine  – % ∆ FVCconstriction Exercise)/  
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Increasing blood flow during exercise helps to deliver appropriate amounts of oxygen to 
active muscle; however older adults appear to have a limited ability to do this.  A 
naturally occurring substance in the circulation called ATP stimulates blood vessels to 
relax thereby facilitating increased blood flow.  Normally, ATP in blood increases during 
exercise in young adults, yet whether this occurs in older adults is unknown.  Our result 
show that ATP levels in the blood do not increase during exercise in aging humans and 
that this relates to reductions in blood flow and oxygen delivery during exercise.  This 



















Aging is associated with impaired control of skeletal muscle blood flow during exercise.  
In young adults, circulating adenosine triphosphate (ATP) aids in the control of muscle 
vascular tone during exercise.  We tested the hypothesis that increases in venous plasma 
[ATP] and ATP release during forearm exercise are impaired in aging humans.  We 
measured forearm blood flow (FBF; Doppler ultrasound) and [ATP], and calculated ATP 
release (FBF x [ATP]) during 5, 15, and 25% MVC rhythmic handgrip exercise in 14 
young (22±1) and 12 older (63±2 yrs) adults.  Deep vnous blood samples were mixed in 
stop solution to preserve [ATP] for plasma measurement.  FBF tended to be lower during 
5% MVC and was lower during 15 and 25% MVC in older adults, and forearm 
vasodilation was reduced at all exercise intensities in older adults (P<0.05).  At rest, there 
were no age-group differences in [ATP] (Y=214±16; O=183±35 nmol/L; P=0.4) or ATP 
release.  [ATP] increased above rest during all exercise intensities in young adults 
(P<0.05); in contrast there was no significant increase in [ATP] in older adults. ATP 
release increased in a graded fashion in both age groups, however this increase was 
blunted ~50-60% at all exercise intensities in older adults (P<0.05 vs young).  ATP 
release was related to FBF during exercise in both groups (r2=0.73).  We conclude that 
the increase in venous plasma [ATP] and ATP release during forearm exercis  is 









ATP, adenosine triphosphate; BMI, body mass index; CtCO2, carbon dioxide content; 
CtO2, oxygen content; DEXA, dual-energy X-ray absorptiometry; ECG, 
electrocardiogram; FBF, forearm blood flow; FO2Hb, fraction of oxyhemoglobin; FVC, 
forearm vascular conductance; HCT, hematocrit; HDL, high-density lipoprotein; LDL, 
low-density lipoprotein; MAP, mean arterial pressure; MBV, mean blood velocity; MVC, 
maximal voluntary contraction; NO, nitric oxide; NOS, nitric oxide synthase; pCO2, 
partial pressure of carbon dioxide; PG, prostaglandin; pO2, artial pressure of oxygen; 



















Metabolically active tissue requires oxygen to generate energy and is thus largely 
dependent on effective convective oxygen transport.  This metabolic demand for oxygen 
must be finely matched with oxygen delivery occurring primarily via the local
modulation of vascular tone (Saltin et al., 1998).  With respect to skeletal muscle, local 
vasodilation and blood flow increases when oxygen demand is heightened during active 
muscle contractions (exercise) (Clifford & Hellsten, 2004; Saltin, 2007), and this 
response is further augmented in humans in the presence of systemic hypoxia indicating 
the sensitivity of blood flow regulatory mechanisms during mismatches in oxygen supply 
and demand (Rowell et al., 1986; Crecelius et al., 2009).  Various lines of evidence 
suggest that innate properties within the vasculature and/or the extravascular tissue may 
sense and produce metabolites capable of evoking vasodilation; however a complete 
understanding of how these mechanisms respond to changes in oxygen requirements 
within the physiological range has yet to become clear (Marshall, 1999; Ellsworth, 2000).  
More recently, it has been proposed that local vascular perfusion may be coupled to 
oxygen carrying capacity of the blood itself.  Given that vasodilation to metabolic 
stressors may be more closely related to the degree of hemoglobin saturation rather than 
oxygen tension (pO2) (Gonzalez-Alonso et al., 2001), the erythrocyte has been 
investigated for its capacity to ‘sense’ oxygen requirements and subsequently release 
vasodilators (such as nitric oxide and ATP) (Ellsworth et al., 2009). 
Three principal mechanisms have been proposed indicating a tight link between 
blood oxygenation and vascular control: (1) the deoxygenation of hemoglobin appears to 




substance may be preserved and charioted via the RBC through the formation of S-
nitrosohemoglobin (SNO-Hb), and (3) the RBC has been shown to release ATP in 
relation to the degree of hemoglobin saturation (Stamler et al., 1997; Jagger et al., 2001; 
Crawford et al., 2006).  With relevance to exercising muscle, our laboratory has taken 
interest in the role of ATP as a circulating vasodilator for a variety of reasons additional 
to mismatches in tissue oxygenation, as acidosis and hypercapnia have also been 
demonstrated to facilitate RBC ATP release (Bergfeld & Forrester, 1992; Ellsworth et al., 
1995).  In addition, mechanical deformation of RBCs, as may be seen with a single 
passage through a capillary network or during muscle contractions, has also been shown 
to release ATP (Sprague et al., 1998; Wan et al., 2008).  Moreover, exercise significantly 
increases blood flow increasing shear stress along endothelial cells which may further 
increase circulating [ATP] and further potentiated flow-mediated vasodilatry effects 
(Liu et al., 2004; Yamamoto et al., 2007).  Collectively, a multitude of stimuli imposed 
during exercise appear to readily facilitate increases in circulating ATP.  Accordingly, 
such findings have been observed in young adults since the late 1960’s (Forrester & Lind, 
1969). 
In addition to evidence supporting the release of ATP in circulation during 
exercise, other characteristics further highlight the unique role that ATP has on vascular 
tone.  Specifically, we and others have demonstrated in young adults that not only does 
ATP evoke substantial vasodilation by activating purinergic-2Y receptors, but can blunt 
sympathetic vasoconstriction in a dose-dependent fashion, unlike other endothelium-
dependent vasodilators such as NO and adenosine (Dinenno & Joyner, 2003; Rosenmeier 




propagated ascending vasodilation and venular-arteriolar communication to aid in the full 
expression of the hyperemic response and O2 elivery (Hester & Hammer, 2002; Winter 
& Dora, 2007).  Taken together, circulating ATP not only aids in the control of muscle 
vascular control at rest and exercise but is unique when measured against other 
endothelium-dependent vasodilators.   
Human aging is the predominant risk factor for cardiovascular disease and is 
characterized by reduced vasodilatory responsiveness to endothelium-dependent stimuli 
(endothelial dysfunction via intra-arterial acetylcholine or shear stress) (Celermajer et al., 
1994; Lloyd-Jones et al., 2009).  Maybe even more importantly, this decline in 
endothelium-dependent vasodilation strongly relates to attenuations in muscle blood flow 
commonly observed in aging humans during elevated oxygen demand situations such as 
exercise(Kirby et al., 2009b).  Given the preponderance of evidence i  vitro indicating 
the endothelium dependence of ATP-mediated vasodilation (Ralevic & Burnstock, 1998; 
Winter & Dora, 2007), we recently tested the hypothesis that vasodilatory responsiveness 
to ATP would be impaired in older adults and lend insight into impaired vascular 
function during metabolic stress.  To our surprise, ATP-mediated vasodilation was not 
impaired in the aged human forearm despite confirmation of endothelial dysfunction as 
evidenced by reduced acetylcholine dilator responsiveness (Kirby et al., 2009a).  Keeping 
in mind that a change in vessel caliber can be dictated by both receptor sensitivity a  well 
as the concentration of the substrate stimulus, we postulated that an inability to increase 
circulating [ATP] may exist in aging humans.  Therefore, in the present invest gation we 
tested the hypothesis that circulating plasma [ATP] and ATP release is diminished during 




which exercise-induced vasodilation and hyperemia are impaired with advancing ge.  To 
the best of our knowledge, to date no information exists regarding circulating plasma 




With Institutional Review Board approval and after written informed consent, a 
total of 14 young and 12 older healthy adult men and women participated in the present 
study.  All subjects were normotensive and free from overt cardiovascular disese as 
assessed from casual blood pressure measurements and a medical history.  Older subjects 
were further evaluated for clinical evidence of cardiopulmonary disease with a physical 
examination and resting and maximal exercise electrocardiograms.  All subjects were 
sedentary to moderately active, non-smokers, not taking any medications including 
antioxidants, and studies were performed after a minimum of a 4-hour fast.  Subjects 
provided written, informed consent after all potential risks and procedures were 
explained.  This study was approved by the Human Research Committee of Colorado 
State University and was performed according to the Declaration of Helsinki. 
 
Arterial Blood Pressure and Heart Rate 
Resting arterial blood pressure was measured non-invasively over the brachial 
artery of the control arm after 30 minutes of supine rest before any experimental trials, 
and just prior to each experimental trial after the study began (Cardiocap/5, Datex-




heart level by finger photoplethysmography (Finometer, FMS, Netherlands) o  the 
middle finger of the control hand during all experimental trials.  Heart rate w s 
determined using a 3-lead ECG (Cardiocap/5, Datex-Ohmeda, Louisville, CO, USA). 
 
Body Composition and Forearm Volume 
Body composition was determined by dual-energy X-ray absorptiometry (DEXA; 
Hologic, Inc; Bedford, MA, USA).  Total forearm volume was calculated from regional 
analysis of the experimental forearm (from the proximal to distal radioulnar joint) from 
whole-body DEXA scans with QDR series software for normalization of individual dr g 
doses.  Body mass index was calculated as bodyweight (kg) divided by height (meters) 
squared. 
 
Forearm Blood Flow and Vascular Conductance 
A 12MHz linear-array ultrasound probe (Vivid7, General Electric, Milwaukee, 
WI, USA) was used to measure brachial artery mean blood velocity (MBV) and br chial 
artery diameter and was placed in a holder securely fixed to the skin as previously 
described by our laboratory (Kirby et al., 2009b).  For blood velocity measurements, the 
probe insonation angle was maintained at <60 degrees and the frequency used was 5 
MHz.  The Doppler shift frequency spectrum was analyzed via a Multigon 500V TCD 
(Multigon Industries, Mt Vernon NY, USA) spectral analyzer from which mean velocity 
was determined as a weighted mean of the spectrum of Doppler shift frequencies.  




diastole and between contractions during steady-state conditions.  Forearm blood flow 
was calculated as: 
FBF = MBV (cm·s-1) * π (brachial artery diameter/2)2 * 60, 
where the FBF is in ml min-1, the MBV is in cm s-1, the brachial diameter is in cm, and 60 
is used to convert from ml s-1 to ml min-1.  Forearm vascular conductance (FVC) was 
calculated as (FBF/MAP) * 100, and expressed as ml min-1 (100 mmHg-1). 
  
Rhythmic Handgrip Exercise 
Maximum voluntary contraction (MVC) was determined for each subject as the 
average of at least three maximal squeezes of a handgrip dynamometer (Stoelting, 
Chicago, IL, USA) that were within 3 percent of each other.  For the dynamic forearm 
exercise trials, weights corresponding to 5, 15, or 25% MVC were attached to a pulley 
system and lifted 4-5 cm over the pulley at a duty cycle of 1 s contraction-2 s relaxation 
(20 contractions per minute) using audio and visual signals to ensure the correct timing. 
We chose these moderate workloads to limit the contribution of systemic haemodynaics 
to forearm vasodilator responses and to eliminate reflex increases in sympathetic nervous 
system activity, and thus isolate the local effects of muscle contraction on vascular tone 
(Kirby et al., 2009b). 
 
Venous Catheterization 
 An 18-gauge, 1.5-cm catheter was placed in retrograde fashion into a vein (that 
appeared to drain muscle rather than skin) of the non-dominant arm for blood sampling.  




set for continuous flushing with heparinized saline and the other to a 10 or 3cc syringe fo  
blood sampling. 
 
ATP – Stop Solution/Blood Sampling 
Venous blood samples were drawn through an 18 gauge catheter directly into a 
pre-heparinized 10cc syringe to minimize hemolysis in which 2ml of blood was gently
and at once expelled into a test tube containing 2.7mL of an ‘ATP-stop solution’ to equal 
a blood:diluent ratio of 1.35 as described by Gorman and colleagues (Gorman et al., 
2003; Gorman et al., 2007).  Briefly, the ‘ATP-stop solution’ (ethylenediaminetetraacetic 
acid (EDTA), NaCl, KCl, tricine buffer, nitrobenzyl thioinosine, forskolin, and 
isobutylmethylxanthine) was made as previously described and has been shown to inhibit 
degradation of ATP via ectonucleotidases and ATP production from other blood sources 
(such as platelets) for up to ~30 minutes (REF).  The blood:diluent volume provided 
sufficient volume for plasma ATP measurements in triplicate and a plasma hemoglobin 
(pHb) measurement per sample.  Blood:diluent samples were then immediately 
centrifuged at 4,000 rpm for 3 minutes at 22°C.  Although this “ATP-stop solution” has 
been shown to maintain stable ATP values for up to ~30 minutes (Gorman et al., 2003; 
Gorman et al., 2007), to minimize any potential modulation of plasma [ATP], samples 
were analyzed for plasma [ATP] and plasma [Hb] directly following centrifugation.  In 
addition, a 2mL blood sample was also drawn into a pre-heparinized 3cc syringe for co-
oximetry blood gas parameters measured via blood gas analyzer (Siemens Healthcare 





Measurement of Plasma [ATP] and [Hb] 
 Directly following centrifugation of blood:diluent samples,100µL of supernatant 
was pipette into 3 individual microcentrifuge tubes for subsequent plasma [ATP] 
determination.  Plasma ATP was measured via the luciferin-luciferase technique where 
light is generated by the reaction of ATP with luciferase and is dependent on 
[ATP](McElroy & DeLuca, 1983).  First, 25µL of Mg2+ solution (44.25 mmol/L, 40 
mmol/L tricine buffer, pH 7.75) was automatically injected into the plasma supernatant to 
counteract the decrease of sample Mg2+ concentration by EDTA.  Two seconds later, 
100µL of luciferase (ATP Bioluminescence Assay Kit CLS II: Roche Diagnostics) was 
automatically injected directly into the same 100µL plasma sample via an automated dual 
injector single tube luminometer in which relative light units (RLU) were colle ted 
(Turner BioSystems 20/20n, Sunnyvale, CA, USA).  After three seconds, cumulative 
light output in RLUs was measured for ten seconds and averaged.  An ATP standard 
curve was created on the day of the experiment prior to all experimental trials and in 
plasma medium from each subject studied.  Specifically, a baseline blood:diluent sample 
was obtained and 90µL plasma samples were spiked with 10µL of varying concentrations 
of ATP standard (equating to 25, 51, 103, 206, 413, 826, 1650 nmol/L).  The average 
standard curve r2 value was 0.996.  Any ATP standard in plasma medium that provided 
>10% variation in RLUs were discarded and reanalyzed.  After accounting for 
background RLUs from an unspiked plasma sample, RLU’s were plotted vs ATP and a 
least squares linear regression line was fit to the data.  Plasma [ATP] was calculated as: 




  To account for venous concentrations of ATP induced from hemolysis, 1mL of 
supernatant from the same blood:diluent sample used for plasma [ATP] measurements 
was pipette into a square 1.5mL methacrylate disposable spectrophotometer cuvett 
(Cole-Parmer No. U-06343-70) and analyzed for plasma Hb via spectrophotometry 
(Molecular Devices SpectraMax).  Plasma Hb was calculated from absorbance (optical 
density) output of 3 wavelengths (415,380,450) using the Harboe method (Harboe, 1959; 
Malinauskas, 1997; Gorman et al., 2007).  This plasma [Hb] reading provided an 
indication of hemolysis (% Hemolysis = {(100 – HCT) * p[Hb]/t[Hb]}*100 ) and 
corresponded with a certain amount of ATP (nmol/L).  ATP concentration (nmol/L) was 
plotted vs plasma [Hb] (range 0-25 mg/L) and data was fit with a linear regression line as 
described by Eric Feigl’s laboratory in 3 young (R2 = 0.98; y=22.145x) and 3 older (R2 
=0.99; y=44.202x) subjects as previously described (Farias et al., 2005; Gorman et al., 
2007).  Further, any blood:diluent sample containing more than 0.5% hemolysis was 
considered technical error and not used in the analysis of data.   
 
Experimental Protocols 
General Experimental Protocol 
The purpose of this protocol was to determine endogenous plasma [ATP] and 
ATP release at rest and during mild, moderate, and moderately-heavy exercis  in young 
and older healthy adults.  Figure 1 is an example of the specific trial timeline.  After 2 
minutes of baseline measurements, subjects performed dynamic rhythmic handgrip 
exercise in the supine position with the non-dominant arm for a total of 15 minutes.  This 




15, and 25% MVC workloads were completed.  Venous blood was sampled for blood 
gases as well as plasma [ATP] and [Hb] at the end of rest and the end of each exercise 
intensity segment.  In addition, measurements for FBF calculation were also determined 
at rest and within each exercise intensity segment.  
 
Data Acquisition and Analysis 
Data was collected and stored on a computer at 250 Hz and analyzed off-line with 
signal-processing software (WinDaq, DATAQ Instruments, Akron, OH, USA).  Baseline 
FBF, HR, and MAP represent an average of the last minute of the resting time period, 
and the steady-state hyperaemic values represent an average of the last minute of each 
exercise intensity (Kirby et al., 2008).  In an effort to be comprehensive, we have also 





All values are reported as means ± S.E.M.  Specific hypothesis testing within over 
time during exercise was performed using repeated measures ANOVA.  In the case of a 
significant F value, Newman-Keuls method for multiple comparisons was used to 
determine where differences occurred.  Statistical significance was set a priori at P<0.05.  
Comparison of the outcome variables at specific time points between the exercis  
conditions were made with unpaired t-tests, and the values within each condition with 




association between variables.  SigmaPlot 11.0 (Systat Software, Inc., San Jose, CA, 




The mean age difference between the young and older adults was 41 years (Table 
1). There were no significant age-group differences in forearm volume, MVC, HDL-
cholesterol, or triglycerides.  Older individuals had a greater BMI, body fat percentage 
and total- and 
LDL-cholesterol (P <0.05; Table 1), although these values were within normal levels.   
 
Forearm and systemic hemodynamic responses at rest and during graded exercise  
Forearm and systemic hemodynamics are presented in Table 2.  Resting FBF, 
FVC, and HR were not different with age.  Although not considered hypertensive, older 
adults had significantly greater MAP at rest compared to younger adults (P<0.05). As 
expected, handgrip exercise at all intensities increased FBF and FVC from baseline in 
both young and older adults and these responses were greater for each graded increase i  
exercise intensity (P<0.05).  Despite increases in FBF and FVC to exercise, older 
compared to young adults had a significantly lower hyperemic response at 15 and 25% 
MVC exercise as well as a significant reduction in forearm vasodilation during all 
exercise workloads (Figures 2A-B; P<0.05).  Both young and older adults significantly 




absolute MAP compared to young (P<0.05).  Heart rate increased with exercise yet was 
not different between age groups. 
 
Venous plasma [ATP] and ATP release at rest and during progressive exercise 
intensity 
  Venous plasma [ATP] was not different at rest between young and older adults 
(214±16 nmol/L vs 183±35 nmol/L; P=0.4).  However during exercise, older adults had 
significantly lower plasma [ATP] concentrations compared to young at all exercise 
intensities (P<0.05) and did not increase [ATP] above baseline (5% = 157±24, 15% = 
232±31, 25% = 248±34 nmol/L; Figure 3).  In contrast, young adults had significantly 
greater [ATP] during all exercise intensities compared to rest conditions (5% = 329±41, 
15% = 359±32, 25% = 407±39 nmol/L; Figure 3; P<0.05).  To account for the impact 
changes in FBF have on [ATP] measurements, ATP release was calculated.  Similar to 
[ATP], ATP release was not different with age during rest (8±1 nmol/min vs 6±1 
nmol/min).  Although both young and older adults had greater ATP release during 
exercise compared to rest, ATP release was significantly reduced with age (5% = 35±7, 
15% = 81±11, 25% = 162±23 nmol/min vs 5% = 13±2, 15% = 39±5, 25% = 71±10 
nmol/min, respectively, Figure 4; P<0.05).  Additionally, forearm vasodilation and ATP 
release were plotted against each other to better visualize the impact of diminished ATP 
release on exercise-mediated vasodilation for both age groups (Figure 5) and for a given 





Effect of exercise intensity and age on blood gas measurements and RBC hemolysis 
indicators 
All blood gas measurements and RBC hemolysis indicators (pHb and % 
hemolysis) are presented in Table 3.  Briefly, the venous blood gas measurements of pH, 
pO2, pCO2, CtO2, CtCO2, and FO2Hb all increased during exercise from rest in both 
young and older adults, however there was no difference with age (P<0.05).  Both 
indicators of RBC hemolysis were increased at 15 and 25% MVC compared to rest in 
young and older adults, and a small but significant increase from rest was observed at 5% 
MVC in older adults, however between age group comparisons did not reveal significant 
differences at rest or any exercise intensity.  As noted in the methods, sample  with > 
0.5% hemolysis were assumed to result from ‘handling’, discarded, and not utilized in 
data analysis; this included 2 samples from the 15% and 1 sample from 25% intensity 
exercise trials.   
To assess the association between [ATP] and potential metabolic stimuli, data 
from rest and all exercise intensities was pooled for both young and older adults.  In 
young adults, [ATP] was significantly correlated to the Hb deoxygenation (FO2Hb) as 
well as pH (r= -0.28; r= -36, respectively, P<0.05).  Conversely, these variables were not 
related to [ATP] in older adults (r= 0.17; r= -0.17; P>0.05) 
 
Discussion 
The primary findings from the present investigation are as follows.  Older healthy 
adults have reduced forearm skeletal muscle blood flow during mild to moderate intensity 




venous plasma [ATP] increases during dynamic forearm exercise in young adults, healthy 
older humans do not increase plasma [ATP] and have significantly lower plasma [ATP] 
than young adults at all exercise intensities.  ATP release (to account for changes in FBF) 
increases during graded intensity forearm exercise regardless of age, yet older adults have 
significantly attenuated ATP release during this metabolic stress.  Importantly, during 
mild to moderate forearm exercise, older adults demonstrate considerably diminished 
ATP release which is associated with significant declines exercise-induced vasodilation. 
Collectively, these data suggest that blunted endogenous ATP release may be a 
mechanism by which skeletal muscle blood flow and oxygen delivery is impaired with 
advancing age in humans. 
 In the present investigation we tested the hypothesis that circulating plasma 
[ATP] and ATP release is diminished during the metabolic stress of exercise in older 
healthy humans and may elucidate a means by which exercise-induced vasodilation and 
hyperemia are impaired with advancing age.  Our rationale for this investigation was two-
fold.  First, aging humans demonstrate impaired vascular control to endothelium 
dependent stimuli that predisposes this population to an increased risk for adverse 
cardiovascular events (Taddei et al., 2001).  With this in mind, we recently predicted that 
ATP-mediated vasodilation would be impaired in healthy aging humans, but in contrast 
found that ATP vasodilatory responsiveness was in fact unaltered compared to young 
adults despite substantially blunted vasodilation to ACH(Kirby et al., 2009a).  Second, 
muscle blood flow and oxygen delivery during exercise is closely associated with 
endothelial health and is known to decline with advancing age.  In combination, previous 




dependent vasodilator ATP in young adults (Gonzalez-Alonso et al., 2002).  However to 
the best of our knowledge, no information exists to date regarding circulating plasma 
[ATP] in older healthy humans at rest or during exercise.   
       As expected, skeletal muscle vasodilation was reduced during exercise in aging 
humans at all exercise intensities and forearm blood flow was reduced at 15 and 25% 
exercise corroborating our recent findings.  Although experiments in the lower limb have 
documented blunted exercise hyperemia in aging humans, current evidence in the upper 
limb is minimal regarding differing exercise workloads and is often limited to post-
exercise assessment via venous occlusion plethysmography.  Nevertheless, our data 
clearly demonstrate and support previous results in the lower limb that aging humans 
have impaired blood flow and oxygen delivery during mild to moderate intensity forearm 
exercise that is mediated by blunted local vasodilation (Kirby et al., 2009b).   
Collective evidence suggests that metabolic stressors along with the mechanical 
stress of exercise can induce ATP release into circulation (Gonzalez-Alonso et al., 2002; 
Wan et al., 2008; Ellsworth et al., 2009).  Repeated muscle contractions of dynamic 
exercise produce a metabolically altered milieu of local hypoxia, hypercapnia, and 
acidosis, as well as evoke increases in arteriolar wall shear stress resultant from 
hyperemia.  In addition, a mechanical stimulus upon the tissue exists due to increases in 
muscle tension developed with exercise.  In the present study, we demonstrate that [ATP] 
increases during exercise in young adults in a fairly graded fashion that is significantly 
greater than rest.  Indeed, calculating ATP release (to account for changes in FBF that 
could dilute the concentration of ATP) in young adults even more clearly demonstrates a 




older adults did not increase [ATP] from rest during exercise at any intensity, and had 
significantly blunted ATP release at each workload when compare to young adults.  
Based on data indicating that RBCs release ATP in response to Hb deoxygenation, 
decreases in pH, and mechanical deformation, and that endothelial cells progressively 
release ATP during graded elevations in shear stress (Bodin & Burnstock, 1995; 
Yamamoto et al., 2007; Ellsworth et al., 2009), we speculate that these functional ATP 
sources in young adults may be significantly impaired in older adults.   
As noted previously, tissue metabolic demand for oxygen must be tightly 
regulated via changes in local vascular tone as the (principal) means of delivering 
oxygen, whereby impairments in vasodilation should closely reflect tissue oxyg n 
delivery assuming arterial oxygen content is quite stable in these healthy populations 
(~20 mg/dL) (Rowell, 1993).  If release of and consequent concentrations of the 
circulating vasodilator ATP are indeed blunted in aging humans, then one would predict
that vasodilation would be effected similarly.  Therefore, we determined the relationship 
between forearm vascular conductance (as an index of vascular tone) and ATP release 
across exercise intensity (Figure 5) and within each workload (Figure 6) for both young 
and older adults.  We in fact did observe a significantly diminished ATP release in the 
older population compared to the young, although the relationship between vasodilation 
and ATP release was not different (i.e. the slope was unchanged; P > 0.05).  Specifically, 
for a given endogenous concentration of ATP the corresponding vasodilation was simil r 
between populations indirectly supporting our previous findings that ATP receptor 
responsiveness is not impaired in healthy aging humans.  Collectively, these data may 




exercise in aging humans are potentially due to a significant attenuation in the ability to 
sense/release ATP into circulation and effectively evoking endothelium-depen nt 
vasodilation.   
 
Potential Mechanisms 
Ellsworth and colleagues aptly demonstrated that RBCs from older hamsters are 
unable to significantly release ATP to hypoxia or acidosis (Ellsworth et al., 1995).  
Accordingly, our blood gas analysis comparison between young and older adults 
indicates that a significant correlation exists between [ATP] and pH (P=0.006) and fO2Hb 
(P=0.037) for young adults, but not in older adults (P=0.25, P=0.26; respectively) 
suggesting an impairment in the ability cells to respond to metabolic and/or mechanical 
stress.  Although in a different diseased population that also exhibits altered blood flow 
responses, accumulating evidence reveals that RBCs from diabetic humans have altered 
signal transduction and consequently blunted ATP release when stimulated (Sprague et 
al., 2006).  Endothelial cells are also known to release ATP to a variety of stimuli that 
occurs during repeated muscle contractions.  Interestingly, caudal artery segments and 
isolated endothelial cells from aged rats have blunted release of ATP (Hashimoto et al., 
1995).  Furthermore, this impairment is exacerbated with higher levels of cholesterol, yet 
offset by modulating the membrane fatty acid composition and with exercise training 
(Hashimoto et al., 1999). Despite these collective and intriguing findings, to date no 
assessment of these stimuli has occurred in cells from healthy aging humans, thus the 




In addition, it is plausible that the observed diminished circulating [ATP] in older
adults is due to an enhancement of ATP degradation enzymes.  Although not directly 
studied in healthy aging humans, ectonucleotidase activity is suggested to be elevat d in a 
variety of disease states that are closely linked with cardiovascular disese and are 
prevalent with advancing age (Duarte e  al., 2007; Lunkes et al., 2008). In particular, this 
is seen in patients with elevated oxidized-LDL, which is typically observed in our aging
population (Kirby et al., 2009a; Kirby et al., 2009b).  In this manner, ATP would be more 
rapidly degraded to its down stream by-products minimizing its robust vasodilator action.  
In general, it is thought that ectonucleotides activity is enhanced as a means of mitigating 
prothrombotic signaling with disease (Schetinger et al., 2007).  Taken together, one may 
predict that a combination of impaired extracellular ATP release and enhanced ATP 
degradation may take place and therefore reduce circulating [ATP] in aging humans.  
 
Experimental Considerations 
A few points should be considered in the present investigation.  First, although 
vasodilation is closely associated with circulating ATP during exercise, to what exact 
ATP contributes to vascular tone at rest and exercise is currently unknown.  Accordingly, 
the use of a P2Y receptor antagonist would be ideal to answer such questions, yet no 
substance is currently available for human use.  Second, with regard to venous plasma 
[ATP] values in humans, an extreme degree of variation has become existent in th  
literature ranging from as low as ~35nmol/L to upwards of ~2000nmol/L(Gorman et al., 
2007).  This discrepancy may be related to how [ATP] is measured but maybe more 




Gorman and colleagues have precisely lain out, we used an ATP “stop-solution” to 
mitigate additional ATP release and ATP degradation that occurs immediately uring 
blood sampling as well as accounted for ATP due to hemolysis, even though in the 
present study we minimized hemolysis to < 0.5% (Gorman et l., 2007).  Nevertheless, 
our results demonstrate clear differences if calculated as a change from rest, which would 
be independent of the absolute venous plasma [ATP].  Finally, we believe the calculation 
of ATP release (FBF x [ATP]/1000) is of considerable importance as elevations in blood 
flow could perhaps ‘dilute’ and confound the interpretation of [ATP] alone.  Possibly, 
one could argue that our findings of blunted ATP release in aging humans is due to a 
reduction in blood flow, however upon closer inspection this unlikely to be the case as 
[ATP] are also low despite elevations in blood flow above rest in aged humans.   
 
Conclusions 
 In healthy young humans, oxygen delivery is effectively matched to changes in 
oxygen demand that occur during metabolic stress, however older adults demonstrated an 
altered control of the vasculature (impaired vasodilation) that may predispose this 
population to increased risk for cardiovascular disease and exercise intolerance.  
Specifically, the collective findings from the present investigation indicate that 
significantly reduced circulating venous plasma [ATP] in older adults may be an 
important mechanisms by which impaired vasodilation and attenuations in oxygen 
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Table 1: Subject Characteristics  
Variable Young Older 
Male:Female 13:1 11:1 
Age (years) 22 ± 1 63 ± 2* 
Body mass index (kg m-2) 24 ± 1 27 ± 1* 
Body fat (%) 17 ± 1 25 ± 2* 
Forearm volume (ml) 1077 ± 40 1121 ± 77 
MVC (kg) 47 ± 3 45 ± 4 
Total cholesterol (mmol l-1) 3.8 ± 0.2 4.7 ± 0.2* 
LDL cholesterol (mmol l-1) 3.4 ± 0.1 4.3 ± 0.2* 
HDL cholesterol (mmol l-1) 0.9 ± 0.5 0.9 ± 0.9 
Triglycerides (mmol l-1) 0.9 ± 0.1 1.0 ± 0.1 
MVC = Maximum voluntary contraction, LDL = Low density lipoprotein, HDL = High 



















FBF = Forearm blood flow, FVC = Forearm vascular conductance, MAP = Mean art rial 









(ml min -1) 
 
FVC 












36 ± 5 
 
 
38 ± 5 
 
 
93 ± 2 
 
 
58 ± 1 
 
Older 33 ± 3 34 ± 3 99 ± 2* 
 
58 ± 3 
 
5% MVC 
Young 98 ± 9 102 ± 8 96 ± 3 
 
60 ± 2 
 
Older 82 ± 7 77 ± 7* 103 ± 3* 
 




Young 220 ± 16 228 ± 13 96 ± 2 
 
62 ± 2 
 
Older 175 ± 14* 161 ± 13* 110 ± 3* 
 




Young 382 ± 30 366 ± 27 104 ± 3 
 
68 ± 2 
 
Older 299 ± 25* 260 ± 23* 116 ± 3* 
 







Table 3.  Blood variables at rest and during exercise with age 
 
 Rest 5% MVC 15% MVC 25% MVC 























































CtO2     





6.3 ±  
0.4* 
6.2 ±  
0.4* 
6.7 ±  
0.5* 
6.0 ±  
0.4* 
7.3 ±  
0.5* 
6.9 ±  
0.3* 
CtCO2  































































































0.24 ±  
0.03 
0.26 ±  
0.03* 
0.25 ±  
0.02* 
0.28 ±  
0.03* 
0.25 ±  
0.02* 
0.30 ±  
0.03* 
 




















Figure 3:  Venous [ATP] to graded intensity rhythmic handgrip exercise.  In young adults, 
[ATP]v was significantly greater than rest at all exercise intensities.  In contrast, older adults did 
not significantly increase [ATP]v for any exercise intensity.  Older adults had significantly 
attenuated [ATP] compared to younger adults for all intensities, however this was not present at 
rest.  † P <0.05 vs rest; * P < 0.05 vs young. 
Figure 4:  [ATP] release into circulation during graded intensity rhythmic handgrip 
exercise.  To account for elevations in FBF that occur during exercise, ATP release was 
calculated.  ATP release increased from rest during all exercise intensity for both young and 
older adults.  Despite this, a significant age-associated decrease in ATP release was observed 
in older adults for each exercise intensity.  * P <0.05 vs young. 
Figure 5:  Association between ATP release and vasodilatation in young and older adults. 
Progressive increases in ATP release relate significantly to greater forearm vasodilation in 
both young and older adults. 
Figure 1: Experimental Timeline.  All subjects rested for two minutes prior to exercise.  
Dynamic rhythmic handgrip exercise was performed in graded fashion at 5, 15, and 25% of the 
subjects’ maximum voluntary contraction using a handgrip pulley system attached to an 
external load.  Dynamic contractions were performed over a range of 4-5 cm at a duty cycle of 
1 sec contraction/2 sec relaxation.  Each bout of exercise intensity was performed for 5 minutes 
totaling a15 minutes for the entire trial.  At the end of rest and each progressive xercise 
intensity, forearm blood flow (FBF), forearm vascular conductance (FVC), [ATP], and blood 
gases were determined.   
Figure 2A-B:  Forearm vascular responses to graded intensity rhythmic forearm 
exercise.   Forearm blood flow (FBF) was greater than rest at each exercise intensity 
regardless of age.  Older adult had significantly reduced FBF at 15 and 25% intensity 
compared to young adults (A).  Forearm vasodilation represented as forearm vascular 
conductance (FVC) increased greater than rest for both age groups at all exercise intensities.  
Significant age-associated reductions in FVC were observed for at all exercis  intensities (B).  
* P <0.05 vs young. 
Figure 6:  Relationship between ATP release and vasodilatation for each exercise intensity 
in young and older adults.  Older adults demonstrate a lower ATP release that is related to 
reduced forearm vasodilatation compared to young adults during (A) 5%, (B) 15%, and (C) 25% 

























































































































































































































































600 Young; r2 = 0.78, (96.84x + 1.46)




















































































































































































CHAPTER VI – OVERALL CONCLUSIONS 
 
Human aging is recognized as a primary risk factor for the development of 
cardiovascular disease.  In particular, older adults typically demonstrate an imp ired 
ability to increase blood flow (and oxygen delivery) in response to various stimuli 
including exercise, and this is largely a result of impaired vasodilation.  An entire host of 
metabolic and chemical substances are known to evoke vasodilation and have been 
proposed to mediate the vasodilatory response observed during muscle contractions.  In 
spite of this, although the study of exercise hyperemia has accrued for over a century, the 
discovery of any one obligatory factor has yet to take place thus creating difficulty when 
trying to pinpoint a specific substance that may explain age-associated impairments in 
active muscle blood flow.  Nonetheless, we have recently turned our attention the 
postulate that circulating nucleotides have an explicit role in the control of vascular tone 
during exercise and a deficit in either the responsiveness or the circulating content of this 
molecule may take place with advancing age.   
In specific, the purine nucleotide ATP is recognized to be released extracellularly 
from endogenous sources into the human circulation from a large host of cells.  As such, 
in vitro evidence indicates that circulating ATP may result from deoxygenation and 
mechanical strain upon endothelial cells as well as erythrocytes and platelets, although 
other cells are recognized to have this ability as well.  However, how the cellular release 
of ATP from these specific sources is altered with human aging is not yet known.  Eve  




humans and to have robust vasodilator action when infused intra-arterially.  More 
recently, evidence indicates that ATP has powerful vasodilatory action in that it can 
evoke elevations in blood flow similar to that observed during maximal exercise and 
results in the ability to significantly blunt (and in some instances abolish) 
sympathetically-mediated vasoconstriction in a dose-response fashion similar to th t seen 
with graded intensity exercise in young adults.  In addition, although heavily touted as an 
endothelium-dependent vasodilator, ATP appears to evoke vasodilation independent of 
nitric oxide, vasodilating prostaglandins, as well as adenosine, and may chiefly cause 
vasodilation via spreading hyperpolarization yet unexplored in humans.  Interesti gly, 
these vasomotor properties are specific to ATP and are typically not observed with the 
downstream adenine nucleotide, AMP, or nucleoside, adenosine. 
To the best of our knowledge, the noted collection of experiments provides novel 
and significant insight into the understanding of how circulating ATP assists in vascular 
control in aging humans.  The collective findings from these studies indicate that 
alterations in the contribution of ATP to vascular tone in aging humans exist and may in
part be a potential mechanism by which aged adults have reductions in oxygen delivery 
to active skeletal muscle.  The specific key findings from the present body of work are as 
follows: 1) exogenous ATP has the ability to blunt α-adrenergic vasoconstriction in 
young adults similar to that observed during exercise, 2) in contrast to our hypothesis, t  
vasodilatory responsiveness as well as 3) the sympatholytic properties of exogenous ATP 
remain intact in aging humans, yet 4) older adults demonstrate reduced venousplasma 
[ATP] and impaired ATP release during graded mild-to-moderate handgrip exercise 




Taken together, it is our belief that the typically observed impairments in skeletal muscle 
vasodilation and the inability to offset sympathetic vasoconstrictor tone during exercise is 
in part due to diminished endogenous levels of circulating ATP.  On the whole, ATP 
appears to be a significant regulator of vascular control in humans, and may act as a 
potential mechanism which in part explains the typically observed reductions in skeletal 
muscle blood flow and oxygen delivery to active tissue in aged humans thereby 
predisposing this population to an elevated risk for cardiovascular diseases, age-related 





















Consent to Participate in a Research Study 
Colorado State University 
 
TITLE OF STUDY:  Regional Blood Flow Control and Vascular Function:  Effects of 
Aging and 
                                 Regular Physical Activity 
PRINCIPAL INVESTIGATOR:  Frank A. Dinenno, Ph.D.  491-3203 
CO-PRINCIPAL INVESTIGATORS:  Matt Hickey, Ph.D.  491-5727 
     Wyatt Voyles, M.D.  663-3107                                                               
 
WHY AM I BEING INVITED TO TAKE PART IN THIS RESEARCH?  You are a man or 
woman between the ages of 18-35 or 55-90 years.  You are either 1) not exercising 
vigorously and regularly, or 2) have exercised vigorously and regularly for a number of 
years.  Our research is looking at the effect of aging and exercise on regional blood flow 
control and how your blood vessels work. 
 
WHO IS DOING THE STUDY?  This research is being performed by Frank Dinenno, 
Ph.D., and Matt Hickey, Ph.D. of the Health and Exercise Science Department, and also 
by Wyatt Voyles, M.D., of the Heart Center of the Rockies.  Trained graduate students, 
undergraduate students, research assistants, or research associates are assisting with 
the research.  These studies are paid for by the National Institute on Aging, a part of the 
US Government. 
   
WHAT IS THE PURPOSE OF THIS STUDY?  The way in which blood flow (and oxygen 
delivery) and blood vessels are regulated by local factors and nerves during exercise 
and during changes in the composition of air you breathe is being studied. Importantly, 
cardiovascular regulation under these conditions might change in older people, it might 
be different between men and women, and it might be affected by regular physical 
exercise.  The purpose of the research is to understand differences in how blood vessels 
work in various groups of adults, in different muscle groups (forearm, thigh, calf), as well 
as in the neck.  The makeup of muscle fibers is also being studied.    
 
WHERE IS THE STUDY GOING TO TAKE PLACE AND HOW LONG WILL IT LAST?  
This whole research project will take place over a period of approximately five years.  
However, your part of this study will be either:  
 ______   1) one or two visits over a several day period, or       ________  (your initials) 
 ______   2) several visits over a few to several weeks.             ________  (your initials) 
 
WHAT WILL I BE ASKED TO DO?  This consent form applies to a large research 
project.  You are only being asked to participate in one part of the total project.  
Depending on the part of the research project that you are involved in, you will be asked 
to participate in some of the following procedures.  Many potential procedures are 
described in the section below.  However, the procedures that you will be asked to do for 
this part of the study have a check mark next to them.  The check marks were put there 
by one of the researchers.  The time associated with each procedure reflects the amount 
of time you will spend performing or undergoing the procedure, not the total time of the 




applies to your participation and specifically how long each session (total time) in the 
laboratory will be.        
 
_____ Health and Physical Activity Questionnaire.  You will be asked to answer some 
questions about your health and exercise habits to determine if you can participate in the 
study. (~20 minutes)                              ________  (your initials) 
 
_____ Pregnancy Test.  If you are female you will be required to have a sample of your 
urine tested for the presence of human chronic gonadotropin (HCG), a hormone which 
indicates whether you may be pregnant.  This will require approximately 1 cup of your 
urine. If you are pregnant or the test indicates that you are pregnant you will not be able 
to participate in this study. (~10 minutes)   ________  (your initials) 
 
_____ Heart Rate and Blood Pressure.  Heart rate will be measured by placing three 
sticky electrodes on your chest and reading the electrocardiogram (ECG) signal.  Blood 
pressure will be measured with an automated machine that requires the placement of a 
cuff around your upper arm (bicep), or a small cuff on your finger. (continuous monitoring 
throughout study)       ________ (your initials) 
 
_____ Graded Exercise Test.  If you are in the 55-90 yr-old age group, you will be 
asked to perform a maximal exercise test on a treadmill under the supervision of a 
physician.  This test will occur in the Human Performance Clinical/Research Laboratory 
in the Department of Health and Exercise Science on the CSU campus.  Sticky 
electrodes will be placed on your chest, and you will walk briskly or jog while the 
steepness of the treadmill is increased.  Your blood pressure and heart beat will be 
closely measured during and immediately after the test.(~1 hour)  
________  (your initials)    
 
_____ Maximal Oxygen Consumption.  VO2max testing will be performed on a treadmill 
while you are walking or running and the steepness of the treadmill is increased until you 
can’t exercise any more.  You will be asked to put your mouth around a scuba-like 
mouthpiece and wear a nose clip to prevent breathing through your nose.  The amount 
of oxygen your body uses for energy will be determined from the oxygen and carbon 
dioxide you breathe in and out during the exercise.  Your heart rate will be measured 
using a heart rate monitor.  Body mass and height will be measured on a medical beam 
scale. (~30 - 45 min)         ________  (your initials) 
 
____ Body Composition.  The fat, muscle, and bone in your body will be measured 
using an x-ray device (dual-energy x-ray absorptiometer) that will scan you from head to 
toe while you lie quietly on a special table for approximately 20 minutes.  The amount of 
x-ray radiation you will receive is extremely low. (~20 minutes)    
        ________  (your initials) 
  
_____ Forearm Volume.  The volume of your forearm will be measured via water displacement.   
You will place your forearm in a large water-filled cylinder, and the spillover of this water 
is collected in a large graduated cylinder to determine the volume.  (~5 minutes)   
        ________  (your initials)                         
 
_____ Forearm Exercise.  You will lay flat on a bed and squeeze your hand and 




secured. The intensity of the exercise will range from very easy to moderately difficult, 
and you will be asked to perform this exercise for ~10 minutes several different times 
throughout the study with plenty of rest in between exercise trials. (1 – 2 hours) 
                                                                                               ________  (your initials) 
  
_____ Calf Exercise.  You will sit in a special chair and squeeze your calf muscles 
(similar to standing on your toes) while your arms, hips, and shoulders are comfortably 
secured.  The intensity of the exercise will range from very easy to moderately difficult, 
and you will be asked to perform this exercise for ~10 minutes several different times 
throughout the study with plenty of rest in between exercise trials.  
(1 – 2 hours)                                                                          ________  (your initials) 
 
_____ Knee Extensor Exercise. You will sit in a special chair and squeeze your thigh 
muscles while your hips and shoulders are comfortably secured.  Your feet will be 
secured in specially designed boots and you will be asked to extend your leg against 
resistance until your ankle is about at the height of your knee, relax back to a regular 
seated position, and then repeat.  The intensity of the exercise will range from very easy 
to moderately difficult, and you will be asked to perform this exercise for ~10 minutes 
several different times throughout the study with plenty of rest in between exercise trials. 
(1 – 2 hours)                                                                          ________  (your initials) 
 
_____ Maximum Voluntary Contraction. This will consist of 3-4 trials where you will 
squeeze your muscles (either forearm, calf, or thigh) and generate as much force as you 
can.  You will be asked to generate as much force over the course of ~3 seconds and 
hold this force another 5 seconds.  After a 2-3 minute rest period, you will be asked to do 
this again.  This is typically used to determine how heavy of exercise you perform so 
everybody is exercising at similar percentages of their maximum. (~ 20 minutes) 
                                                                                              ________  (your initials) 
 
_____  Exercise Training.   
 Forearm:  You will be instructed to exercise five times per week, for a total of four 
weeks.  You will be given a special exercise device and will be instructed to exercise 
with your non-dominant forearm squeezing your muscles 12 times per minute at 30-35% 
of your maximum until you can’t exercise any more.  When you are able to exercise at 
this initial workload for 30 minutes, the workload will be increased.  You will need to visit 
the laboratory once per week to adjust the training workload as your performance 
improves.           ________  (your initials) 
 
 Calf:  You will be instructed to exercise five times per week, for a total of four 
weeks.  You will be instructed to exercise with your calf muscles and squeeze this 
muscle 12 times per minute at 30-35% of your maximum until you can’t exercise any 
more.  You will be instructed to perform calf extension exercise in the upright position 
with added weight (if necessary) to achieve the pre-determined workload.  When you are 
able to exercise at this initial workload for 30 minutes, the workload will be increased.  
You will need to visit the laboratory once per week to adjust the training workload as 





 Knee extensor:  You will be instructed to exercise 3 times per week, for a total of 
eight weeks.  You will be required to perform the training studies in the laboratory under 
supervision.  Each training session will be 60 minutes.  The first two weeks will consist of 
short (5-10 min) high intensity exercise bouts, whereas the second two weeks will 
consist of long (15-45 min) low intensity exercise bout.  This pattern of training will be 
repeated to attain a total training period of eight weeks.  As your exercise performance 
improves, the training workload will be adjusted accordingly.    ________  (your initials) 
 
 Whole-body:  You will be instructed to exercise 5 times per week, 40-50 minutes 
per exercise session at 60-85% of your maximum heart rate, for a total of twelve weeks.  
You will be asked to cycle, walk, jog, or run during this training period.  You will be 
taught how to use heart rate monitors (provided by the lab) in order to train at the proper 
intensity as well as to record your exercise sessions.   ________  (your initials)         
 
____  Ischemic Exercise.  You will exercise your calf or forearm with a blood pressure 
cuff on your thigh or upper arm that is inflated very tightly to temporarily block the blood 
flowing to your muscle.  You will be asked to perform this exercise for ~10 minutes 
several different times throughout the study with plenty of rest in between exercise trials. 
(20 – 30 minutes)       ________  (your initials) 
 
____  Cold Pressor Test.  You will place your hand or foot in ice water for 2-3 minutes 
on several occasions. (~10 minutes)    ________  (your initials) 
 
____  Lower Body Negative Pressure.  You will be placed in a sealed wooden 
chamber while you are laying flat on a bed.  The chamber is sealed at your waist.  Using 
a standard vacuum that is attached to the chamber, suction will be applied to mimic what 
happens when you go from laying to standing up. This will occur several times 
throughout the study for about 15 minutes at a time. (~ 1 hour)     
        ________  (your initials) 
 
____  Up-right or head-down tilting.  You will be lying on a bed that is specially 
designed to be tilted ~60 degrees upright, or tilted downward ~10 degrees.  This mimics 
what happens when you go from laying to standing up, and vice versa. (~ 1 hour)   
        ________  (your initials) 
 
____  Forearm Negative/Positive Pressure.  You will place your forearm in a sealed 
chamber up to your elbow.  Application of suction (like a vacuum) increases blood flow 
to your arm, whereas the opposite pressure reduces blood flow to your arm. (1-2 hours) 
        ________  (your initials) 
 
____  Brachial Artery Compression.  A special device that is mounted to a frame 
above your forearm will be placed over your brachial artery at the elbow.  When this 
device presses down on your arm, it will temporarily reduce the amount of blood to your 
forearm.  This will be performed for approximately 5 minutes at a time, and will occur 
several times throughout the study.  (1-2 hours)  ________ (your initials)  
 
____  Breathing a low Oxygen or high Carbon Dioxide Gas Mixture.  The purpose of 
this test is to mimic what happens when you go up to altitude.  You will be asked to 




breathing through your nose.  The amount of oxygen or carbon dioxide you are 
breathing will be changed carefully with a specially designed system, and you will 
breathe this for a maximum of 20 minutes at a time.  You will be asked to do this several 
times throughout the study, with plenty of time in-between each trial.  The amount of 
oxygen that is in your blood will be measured with a light sensor on your fingertip or 
earlobe.  (1-1.5 hours)       ________  (your initials)  
 
____ Venous Occlusion Plethysmography.  The blood flow in your forearm or calf will 
be measured by the use of blood pressure cuffs around your upper arm or thigh, and 
around your wrist or ankle.  These cuffs will be inflated and deflated periodically.  A 
sensitive gauge (similar to a rubber band) will also be placed around the maximum 
circumference of your forearm or calf. (2-3 hours)                 ________  (your initials)                                                    
 
____  Doppler Ultrasound.  The blood flow in your arm, leg, neck, or brain will be 
measured using an ultrasound machine which produces sound waves to measure your 
blood vessel size and the speed of your blood.  This also provides information about 
how elastic or stiff your blood vessels are. (2-3 ho   ________  (your initials) 
 
____  Reactive Hyperemia.  A blood pressure cuff will be placed on your upper arm or 
thigh and inflated really tight to temporarily block the blood to your forearm or calf.  After 
5, 10, or 15 minutes, the cuff will be released and the blood flow in your forearm or calf 
will be measured.  This test is a measure of how much your blood vessels can relax and 
will be repeated several times throughout the study. (1- 1.5 hours) 
          ________  (your initials)  
 
____  Flow-Mediated Vasodilation.  A blood pressure cuff will be placed on your 
forearm or your calf and inflated really tight to temporarily block the blood to your hand 
or foot.  After 5, 10, or 15 minutes, the cuff will be released and the diameter changes of 
the blood vessels in your arm or leg will be measured using Doppler ultrasound.  In 
some cases, your hand or foot will be warmed up for 15 minutes and the changes in 
blood vessel diameter will be measured. This will be repeated several times throughout 
the study. (1-1.5 hours)           ________  (your initials) 
 
____ Sympathetic Nervous System Activity.  The measurement of sympathetic 
nervous system activity involves measuring the activity of one of your nerves on the side 
of your knee.  Two small microelectrodes (small needles) will be placed through your 
skin.  The position of one of the electrodes will be moved back and forth through your 
skin while a very small electrical impulse (1-2 volts) is passed through the electrode.  
This search procedure will continue until the electrode being moved causes your foot to 
twitch.  This procedure will take between 5-60 minutes.  When a foot or hand twitch is 
observed, measurement of the activity of the sympathetic nervous system will begin. (2-
3 hours)                                    ________  (your initials) 
 
____ Blood Sample.  Up to 100 ml (approximately 7 tablespoons) of your blood will be 
drawn from a vein on the front of your elbow or artery in a standard fashion using a 
sterilized hypodermic needle. (~15 minutes)                 ________  (your initials) 
 
** For Arterial Catherization, Venous Catheterization, or Muscle Biopsy:  If you are 
allergic to lidocaine or novacaine, or have had a negative reaction to medicines injected 
while at the dentist, you should notify us immediately and not have any of these 





____ Venous Catheterization.  Your skin will be cleaned and a catheter (plastic needle) 
will then be inserted on the front side of your elbow and secured to the skin.  In some 
cases, a local anesthetic might be used to reduce any discomfort. (~2-4 hours) 
                                                 ________  (your initials) 
 
____ Brachial Artery Catheterization.  Your skin will be cleaned and a local anesthetic 
will be given with a small needle to numb the area where the catheter will be placed 
(front side of your elbow).  The catheter (plastic needle) will then be inserted and 
secured to the skin. (~2-4 hours)      ________  (your initials) 
   
____ Femoral Artery Catheterization.  Your skin will be cleaned and a local anesthetic 
will be given with a small needle to numb the area where the catheter will be placed 
(about half way between your hip bone and groin on the front side of your leg).  The 
catheter (plastic needle) will then be inserted and secured to the skin. (~2-4 hours) 
            ________  (your initials) 
 
____  Drug Administration (~ 2 - 4 hours).  The administration of one of more of the 
following drugs might occur several times throughout the study. 
 
Vasoconstrictors – cause temporary narrowing of the blood vessels (minutes) 
___ Tyramine 








Vasodilators – temporarily relax the blood vessels (minutes) 
___ Acetylcholine 
___ Adenosine 
___ Sodium Nitroprusside 
___ L-Arginine 
___ Phentolamine 
___ Adenosine Triphosphate (ATP) 
 
No major effects 
___ Ascorbic Acid (Vitamin C) 
___ Propranolol 
        ________  (your initials) 
 
____ Muscle Biopsy.  A sample of muscle will be taken from a muscle on the outside of 
your thigh.  This will take place under the supervision of a medical doctor in the 
Hartshorn Health Center on the CSU campus.  Your skin will be temporarily numb using 
lidocaine, a medicine similar to novacaine.  After deadening the skin, a ¼ inch incision, 
or cut, is made in the skin over the muscle using a sterilized scalpel.  The sample is 
obtained using a sterilized sampling needle.  The muscle sample obtained is usually 
about ½ the size of the eraser on the end of a pencil.   You will not have to reduce your 




a few days.  You will receive written instructions regarding care of the incision, and a 
telephone number to contact if you have any questions. (30 - 45 minutes) 
                                                                                               ________  (your initials)     
 
FUTURE USE OF BLOOD OR MUSCLE SAMPLES 
It is possible that we may want to use any extra blood or muscle tissue for future research 
not described in this consent form.  For example, this may include determination of 
certain gene expressions that relate to various measures of cardiovascular function 
measured as part of this study.  This information will remain private as will all of the data 
collected from the study.   
Only choose one of the following:    
 
_____ I give permission for the use of my blood or muscle tissue collected as part of the 
current study only.                ________  (your initials) 
 
_____ I give permission for the use of my blood or muscle tissue for the current study as 
well as for future studies.                 ________  (your initials) 
 
 
ARE THERE REASONS WHY I SHOULD NOT TAKE PART IN THIS STUDY? 
If you are not 18-35 or 55-90 years of age, are pregnant, are a regular smoker, or have 
any diseases that would affect our measurements or significantly increase the risks 
associated with this study, we will not be able to include you in the research.  
 
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS?  
(The procedures that apply to your proposed participation are checked)  
 
 _____  Health and Physical Activity Questionnaire – there are no known risks 
associated with answering health questions.  All information is kept strictly 
confidential.                             ________  (your initials) 
 
 _____  Graded Exercise Test – there is a risk of fatigue (temporary muscle tiredness), 
muscle strain, heart beat abnormalities (arrhythmias), a 0.01% chance of death (in 
people who have heart problems), a 0.02% risk of cardiac arrhythmias that would 
require you to go to a hospital (in people who have heart problems), and a risk of an 
increase or decrease in blood pressure.      ________  (your initials) 
 
 _____ Maximal Oxygen Consumption – There is the possibility of fatigue, muscle 
strains, heart rhythm abnormality, and change in blood pressure.  There is the 
possibility of falling off of the treadmill.  Incidence of myocardial infarction (MI) is also 
a risk.  1 in 10,000 individuals with cardiovascular disease may die and 4 in 10,000 
may have abnormal heart rhythms or chest pain.      ________  (your initials) 
 
 _____ Body composition (DEXA) scan – the risks associated with the DEXA are very 
low.  The radiation you will receive is less than 1/3000th of the Food and Drug 
Administration (FDA) limit for annual exposure.  The FDA is a government 
organization responsible for medical safety.   In other words, you could receive 3000 
DEXA scans in a single year and still not meet the FDA limit for radiation exposure.  
In this study you will receive one scan.  The more radiation you receive over the 
course of your life, the greater the risk of having cancerous tumors or of inducing 




these risks, but the exact increase in such risks is not known.  Women who are 
pregnant or could be pregnant should receive no unnecessary radiation and should 
not participate in this study.                                                ________  (your initials) 
  
 
 _____ Muscle contractions (Exercise) – There is a slight risk of muscle strain and 
muscle soreness resulting from brief strong muscle contractions.  Soreness should 
not last more than two days or affect your normal function.________  (your initials)                              
 
 _____ Exercise training – There is a slight risk of muscle strain and muscle soreness  
resulting from brief strong muscle contractions.  Soreness should not last more than 
two days or affect your normal function and should get progressively less as training 
continues.                                                              ________  (your initials) 
 
 _____ Ischemic Exercise – There is a risk of temporary discomfort and possible 
cramping in the forearm or calf during and after the exercise.  These symptoms will be 
relieved when the exercise stops.          ________  (your initials) 
 
 _____ Cold Pressor Test – There is a risk of temporary discomfort of the hand or foot.  
In rare cases, subjects might feel light-headed or nauseous.  These symptoms will be 
relieved when the hand or foot is removed from the ice water and wrapped in a 
blanket.              ________  (your initials) 
 
 _____ Lower Body Negative Pressure- There is a small risk of feeling nauseous or 
fainting.  These symptoms will be relieved when the vacuum is turned off.   
                ________  (your initials) 
                
 _____ Up-right or Head-down Tilting – Small risk of feeling nausea or fainting during 
up-right tilt.  These symptoms will be relieved when the table is tilted back and the 
subject is lying supine.  There are no known risks for head-down tilt.   
                ________  (your initials) 
 
 _____ Forearm Positive/Negative Pressure – There is a small risk of slight discomfort 
or cramping if performing forearm exercise at the same time. 
                ________  (your initials) 
 
 _____ Brachial Artery Compression – There is a risk of slight discomfort at the site of 
compression (elbow).  There is also a risk of slight discomfort or cramping if 
performing forearm exercise at the same time.        ________ (your initials) 
 
 _____ Breathing a low oxygen or high carbon dioxide content gas mixture- The risks 
associated with this include light-headedness, headache and fainting.  However, we 
will be monitoring all of your vital signals and will stop the procedure if this occurs.  
Symptoms will end momentarily after breathing normal room air.             
                            ________  (your initials) 
 
 _____ Venous Occlusion Plethysmography- There is a risk of temporary discomfort 
of the hand or foot when the blood pressure cuffs are inflated.  





 _____ Reactive Hyperemia/Flow-Mediated Vasodilation- There is a risk of temporary 
discomfort of the upper arm or thigh when the blood pressure cuffs are inflated.  The 
discomfort might be greater the longer the cuffs are inflated. 
                   ________  (your initials)  
 
 _____ Sympathetic Nervous System Activity – Some subjects experience a 
temporary (seconds) pain and discomfort while the microelectrodes are being 
inserted. After the procedure there is a small risk of numbness, pins and needles type 
sensations, or pain which lasts 1-3 days. In very rare cases, numbness, pins and 
needles type sensations, or pain in the leg or arm has lasted several weeks or months 
(1-3 in 1000).  These problems can be minimized by only having experienced 
individuals perform this technique. In addition, by minimizing the time to find the nerve 
to less than 60 minutes, the risk of unpleasant after-effects is reduced even more. 
                                                                                                   ________  (your initials) 
 
 _____ Blood sample – The risks associated with blood drawing include bruising, slight 
risk of infection, soreness, and fainting.  These are minor risks which usually do not 
last more than one day if they occur.                                                        
                ________  (your initials) 
 
 _____ Venous Catheterization- The risk of allergic reaction to lidocaine is extremely 
low. There is a risk of bruising, slight risk of infection, local soreness, and fainting. 
                    ________  (your initials) 
 
 _____ Arterial Catheterization – The risk of allergic reaction to lidocaine is extremely 
low.  There is a risk that pain or discomfort may be experienced when the catheter is 
inserted in the artery, and local soreness after the study.  In about 1 in 10 cases a 
small amount of bleeding under the skin will cause a bruise.  There is about a 1 in 
1,000 risk of infection or significant blood loss.  In about 1 in 4,000 damage may occur 
to the artery requiring surgery.            ________  (your initials) 
 
 _____ Drug Administration - The risks associated with drug administration include 
temporary increases or decreases in blood pressure and heart rate.  In the case of 
clonidine and dexmedetomidine, you might experience mild drowsiness.  These 
symptoms should resolve when the drug stops.  With any of the vasoconstrictor 
drugs, there is a slight risk that ischemia (lack of blood to the tissues) could occur.   
Risks of these effects are minimized by calculating the amount of drug given relative 
to the size of your forearm or leg, and not the entire body.  Finally, there is a potential 
risk of an allergic reaction to vasoactive drug administration.  If you are allergic to 
aspirin, you should not participate.       ________  (your initials) 
 
 _____ Muscle Biopsy – The risks associated with the muscle sample procedure 
include discomfort, soreness in that muscle, bruising, infection, and minor scarring.  
The discomfort and localized soreness are likely, but generally last only 24-48 hours.  
Temporary scarring is also expected.  How wounds heal over time is different 
between people.  The scar will only be about ¼ inch long, and is usually difficult to 
distinguish 8-12 months after the procedure.  The risk of bruising is low, and 
infections are extremely rare.             ________  (your initials) 




 It is not possible to identify all potential risks in research procedures, but the 
researcher(s) have taken reasonable safeguards to minimize any known and 
potential, but unknown, risks. 
 
WILL I BENEFIT FROM TAKING PART IN THIS STUDY?  There are no direct benefits 
to you for participating in this study beyond receiving information on your body 
composition and cardiovascular risk factors. 
 
DO I HAVE TO TAKE PART IN THE STUDY?   Your participation in this research is 
voluntary.  If you decide to participate in the study, you may withdraw your consent and 
stop participating at any time without penalty or loss of benefits to which you are 
otherwise entitled.   
 
 WHAT WILL IT COST ME TO PARTICIPATE?  There is no cost to you for participating 
except that associated with your transportation to our facilities. 
 
WHO WILL SEE THE INFORMATION THAT I GIVE?  We will keep private all research 
records that identify you, to the extent allowed by law. Your information will be combined 
with information from other people taking part in the study. When we write about the 
study to share it with other researchers, we will write about the combined information we 
have gathered. You will not be identified in these written materials. We may publish the 
results of this study; however, we will keep your name and other identifying information 
private.  
 
We will make every effort to prevent anyone who is not on the research team from 
knowing that you gave us information, or what that information is.  For example, your 
name will be kept separate from your research records and these two things will be 
stored in different places under lock and key. You should know, however, that there are 
some circumstances in which we may have to show your information to other people.  For 
example, the law may require us to show your information to a court or to the Human 
Research Committee at CSU.   
 
CAN MY TAKING PART IN THE STUDY END EARLY?  Your participation in the study 
could end in the rare event of muscle strain, if you become pregnant, or if you miss an 
excessive number of appointments.   
 
WILL I RECEIVE ANY COMPENSATION FOR TAKING PART IN THIS STUDY?  For 
experiments that involve the blood sample, muscle sample, fine wire electrodes, and 
arterial or venous catheterization, you will be paid $25/hour.  
 
WHAT HAPPENS IF I AM INJURED BECAUSE OF THE RESEARCH?  Please be 
aware that for this study the University has made special arrangements to provide 
initial medical coverage for any injuries that are directly related to your participation in 
this research project. The research project will provide for the coverage of reasonable 
expenses for emergency medical care related to the treatment of research-related 
injuries, if necessary. 
 
LIABILITY: 
Because Colorado State University is a publicly-funded, state institution, it may have 
only limited legal responsibility for injuries incurred as a result of participation in this 




(Colorado Revised Statutes, Section 24-10-101, et seq.).  In addition, under Colorado 
law, you must file any claims against the University within 180 days after the date of the 
injury.  
 
In light of these laws, you are encouraged to evaluate your own health and disability 
insurance to determine whether you are covered for any physical injuries or emotional 
distresses you might sustain by participating in this research, since it may be necessary 
for you to rely on your individual coverage for any such injuries. Some health care 
coverages will not cover research-related expenses. If you sustain injuries, which you 
believe were caused by Colorado State University or its employees, we advise you to 
consult an attorney. 
 
Questions concerning treatment of subjects' rights may be directed to Celia S. Walker at 
(970) 491-1563.  
 
WHAT IF I HAVE QUESTIONS?  Before you decide whether to accept this invitation to 
take part in the study, please ask any questions that might come to mind now.  Later, if 
you have questions about the study, you can contact the principal investigator, Frank 
Dinenno, Ph.D., at (970)491-3203, or via email at fdinenno@cahs.colostate.edu.  If you 
would like to ask a medical doctor about your participation in the study, you may contact 
Wyatt Voyles, M.D. at 663-3107.   If you have any questions about your rights as a 
volunteer in this research, contact Celia Walker, Director of Regulatory Compliance, at 
970-491-1553.  We will give you a copy of this consent form to take with you. 
 
 
Your signature acknowledges that you have read the information stated and willingly 
sign this consent form.  Your signature also acknowledges that you have received, on 
the date signed, a copy of this document containing 9 pages. 
  
_________________________________________      _____________________ 
Signature of person agreeing to take part in the study      Date 
 
_________________________________________ 
Printed name of person agreeing to take part in the study 
 
_______________________________________     _____________________ 
Name of person providing information to participant      Date 
 
_________________________________________    
Signature of Research Staff 
 
 
** List of Contact Numbers in Case of Medical Emergency 
    Wyatt Voyles, M.D.      Work: 970-221-1000 (24 hours a day) 
    Poudre Valley Hospital Emergency  970-297-6250 
    Frank A. Dinenno, Ph.D.    Work: 970-491-3203 
           Home: 970-266-1719 
 
